Nelliebear personal page - To The Moon

Nelliebear

No personal profile

3Follow

1Followers

0Topic

0Badge

2022-05-09

$Zymeworks Inc.(ZYME)$ do people realise that the projected share price from analysts are in the range of $15 to 45?! 😅 However, Zymeworks is falling to its all time low 🤯 how?

2022-04-17

Absolutely gambling and draws in the opportunists before dropping us all in it. Not exactly a skill but just how long you want to tag along

Newly public Genius Group stock drops 50% following monster IPO

2022-05-14

$Actelis Networks Inc(ASNS)$ does this look like $4 a share?! 😅

2022-09-15

💪 Keep going

Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery

2023-03-16

Keep the faith

Sorry, the original content has been removed

2022-12-20

💪

Sorry, the original content has been removed

2022-12-14

👍

Sorry, the original content has been removed

2022-12-14

👍

Sorry, the original content has been removed

2022-10-07

👍

Sorry, the original content has been removed

2022-09-22

Keep going 👍

Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?

2022-09-20

Keep going 👍

Sorry, the original content has been removed

2022-09-19

Keep going 💪

Sorry, the original content has been removed

2022-09-15

Keep going 💪

Sorry, the original content has been removed

2022-09-07

Keep going 💪

Sorry, the original content has been removed

2022-09-07

Keep going 💪

Hollysys Stock: Possible Take-Private Deal? (NASDAQ:HOLI)

2022-09-02

💪 Keep going

Sorry, the original content has been removed

2022-09-02

💪 Keep going

Exclusive-Hollysys management to lead take-private deal at $1.8 billion valuation -sources

2022-08-31

💪💪

BRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing

2022-08-26

Keep going

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4099579894850160","uuid":"4099579894850160","gmtCreate":1636476828583,"gmtModify":1636476828583,"name":"Nelliebear","pinyin":"nelliebear","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":40,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.03","exceedPercentage":"93.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9943069212,"gmtCreate":1678970053837,"gmtModify":1678970057873,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep the faith&nbsp;","listText":"Keep the faith&nbsp;","text":"Keep the faith","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943069212","repostId":"2319635989","repostType":2,"repost":{"id":"2319635989","kind":"highlight","pubTimestamp":1678969541,"share":"https://ttm.financial/m/news/2319635989?lang=&edition=fundamental","pubTime":"2023-03-16 20:25","market":"us","language":"en","title":"Needham Keeps Their Buy Rating on Esperion (ESPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2319635989","media":"TIPRANKS","summary":"Needham analyst Serge Belanger maintained a Buy rating on Esperion (ESPR – Research Report) today an","content":"<div>\n<p>Needham analyst Serge Belanger maintained a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $12.00. The company’s s...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/needham-keeps-their-buy-rating-on-esperion-espr?utm_source=itigerup.com&utm_medium=referral\">Web Link</a>\n\n</div>\n","source":"tipranks_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Needham Keeps Their Buy Rating on Esperion (ESPR)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeedham Keeps Their Buy Rating on Esperion (ESPR)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-16 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/blurbs/needham-keeps-their-buy-rating-on-esperion-espr?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Needham analyst Serge Belanger maintained a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $12.00. The company’s s...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/needham-keeps-their-buy-rating-on-esperion-espr?utm_source=itigerup.com&utm_medium=referral\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ESPR":"Esperion Therapeutics Inc."},"source_url":"https://www.tipranks.com/news/blurbs/needham-keeps-their-buy-rating-on-esperion-espr?utm_source=itigerup.com&utm_medium=referral","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2319635989","content_text":"Needham analyst Serge Belanger maintained a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $12.00. The company’s s...","news_type":1},"isVote":1,"tweetType":1,"viewCount":352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9926346415,"gmtCreate":1671475343437,"gmtModify":1676538542689,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926346415","repostId":"2292878348","repostType":2,"repost":{"id":"2292878348","kind":"highlight","pubTimestamp":1671460632,"share":"https://ttm.financial/m/news/2292878348?lang=&edition=fundamental","pubTime":"2022-12-19 22:37","market":"us","language":"en","title":"Cosmos Health prices $32.5M direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2292878348","media":"seekingalpha","summary":"Cosmos Health (NASDAQ:COSM) has entered into securities purchase agreements with institutional inves","content":"<html><body><ul>\n<li>Cosmos Health (<span>NASDAQ:COSM</span>) has entered into securities purchase agreements with institutional investors for the purchase and sale of 2.83M shares.</li>\n<li>The combined purchase price for one share of common stock and one warrant will be $11.50. </li>\n<li>Gross proceeds from the offering will be ~$32.5M. </li>\n<li>Net proceeds from the offering for working capital and general corporate purposes</li>\n<li>The offering is expected to close on or about December 21, 2022. </li>\n</ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cosmos Health prices $32.5M direct offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCosmos Health prices $32.5M direct offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3918419-cosmos-health-prices-325m-direct-offering><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cosmos Health (NASDAQ:COSM) has entered into securities purchase agreements with institutional investors for the purchase and sale of 2.83M shares.\nThe combined purchase price for one share of common ...</p>\n\n<a href=\"https://seekingalpha.com/news/3918419-cosmos-health-prices-325m-direct-offering\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4175":"保健护理产品经销商","COSM":"COSMOS HEALTH INC"},"source_url":"https://seekingalpha.com/news/3918419-cosmos-health-prices-325m-direct-offering","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2292878348","content_text":"Cosmos Health (NASDAQ:COSM) has entered into securities purchase agreements with institutional investors for the purchase and sale of 2.83M shares.\nThe combined purchase price for one share of common stock and one warrant will be $11.50. \nGross proceeds from the offering will be ~$32.5M. \nNet proceeds from the offering for working capital and general corporate purposes\nThe offering is expected to close on or about December 21, 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921919543,"gmtCreate":1670952901482,"gmtModify":1676538466261,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919543","repostId":"2291739039","repostType":2,"repost":{"id":"2291739039","kind":"highlight","pubTimestamp":1670863934,"share":"https://ttm.financial/m/news/2291739039?lang=&edition=fundamental","pubTime":"2022-12-13 00:52","market":"us","language":"en","title":"Harpoon adds 122% on updated Phase 1 data for multiple myeloma therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2291739039","media":"seekingalpha","summary":"Nano cap biotech Harpoon Therapeutics (NASDAQ:HARP) added ~122% in the morning hours Monday after th","content":"<html><body> <p>Nano cap biotech Harpoon Therapeutics (<span>NASDAQ:HARP</span>) <span>added ~122%</span> in the morning hours Monday after the company disclosed updated interim data from its Phase 1 clinical trial for investigational cancer therapy HPN217 in relapsed/refractory multiple myeloma (RRMM).</p> <p>The company said that<span> data from 62 patients as of the Oct. 17 data cut indicated a 77% (10/13) objective response rate (ORR) for HPN217 across the highest doses (12 and 24 mg).</span></p> <p>Responses were durable, with 86% (18/21) of responders remaining on study treatment, including many patients for more than a year, the Harpoon (HARP) added.</p> <p>Regarding safety, 29% of patients experienced low-grade cytokine release syndrome across the highest step dose regimens (12% Grade 1 and 18% Grade 2), Harpoon (HARP) said, adding that effects were mainly linked to earlier doses.</p> <p>Results were part of a presentation at the ongoing American Society of Hematology (ASH) Annual Meeting.</p> <p>The enrollment in the Phase 1 trial is expected to complete in H1 2023.</p> <p>AbbVie (ABBV) has inked a licensing deal with Harpoon (HARP) for HPN217, which is designed to target the B-cell maturation antigen (BCMA). Per the terms, the pharma giant can exercise an option to license HPN217 after the Phase 1 trial concludes.</p> <p>Seeking Alpha contributor E. Roudasev issued a Strong Buy recommendation on Harpoon (HARP) in September, calling the clinical-stage biotech “a bargain” with limited downside risk.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harpoon adds 122% on updated Phase 1 data for multiple myeloma therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarpoon adds 122% on updated Phase 1 data for multiple myeloma therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-13 00:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3916194-harp-stock-jumps-on-updated-phase-1-data-for-multiple-myeloma-therapy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nano cap biotech Harpoon Therapeutics (NASDAQ:HARP) added ~122% in the morning hours Monday after the company disclosed updated interim data from its Phase 1 clinical trial for investigational cancer ...</p>\n\n<a href=\"https://seekingalpha.com/news/3916194-harp-stock-jumps-on-updated-phase-1-data-for-multiple-myeloma-therapy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303505360/image_1303505360.jpg","relate_stocks":{"LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","BK4585":"ETF&股票定投概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK4534":"瑞士信贷持仓","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4139":"生物科技","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4559":"巴菲特持仓","HARP":"Harpoon Therapeutics Inc.","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4550":"红杉资本持仓","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","ASH":"亚什兰","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H"},"source_url":"https://seekingalpha.com/news/3916194-harp-stock-jumps-on-updated-phase-1-data-for-multiple-myeloma-therapy","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2291739039","content_text":"Nano cap biotech Harpoon Therapeutics (NASDAQ:HARP) added ~122% in the morning hours Monday after the company disclosed updated interim data from its Phase 1 clinical trial for investigational cancer therapy HPN217 in relapsed/refractory multiple myeloma (RRMM). The company said that data from 62 patients as of the Oct. 17 data cut indicated a 77% (10/13) objective response rate (ORR) for HPN217 across the highest doses (12 and 24 mg). Responses were durable, with 86% (18/21) of responders remaining on study treatment, including many patients for more than a year, the Harpoon (HARP) added. Regarding safety, 29% of patients experienced low-grade cytokine release syndrome across the highest step dose regimens (12% Grade 1 and 18% Grade 2), Harpoon (HARP) said, adding that effects were mainly linked to earlier doses. Results were part of a presentation at the ongoing American Society of Hematology (ASH) Annual Meeting. The enrollment in the Phase 1 trial is expected to complete in H1 2023. AbbVie (ABBV) has inked a licensing deal with Harpoon (HARP) for HPN217, which is designed to target the B-cell maturation antigen (BCMA). Per the terms, the pharma giant can exercise an option to license HPN217 after the Phase 1 trial concludes. Seeking Alpha contributor E. Roudasev issued a Strong Buy recommendation on Harpoon (HARP) in September, calling the clinical-stage biotech “a bargain” with limited downside risk.","news_type":1},"isVote":1,"tweetType":1,"viewCount":330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921919295,"gmtCreate":1670952878417,"gmtModify":1676538466259,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919295","repostId":"2291146287","repostType":2,"repost":{"id":"2291146287","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1670867520,"share":"https://ttm.financial/m/news/2291146287?lang=&edition=fundamental","pubTime":"2022-12-13 01:52","market":"us","language":"en","title":"Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2291146287","media":"Dow Jones","summary":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HARP\">Harpoon Therapeutics Inc.</a> surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n</p>\n<p>\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n</p>\n<p>\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n</p>\n<p>\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n</p>\n<p>\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2022 12:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-12-13 01:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HARP\">Harpoon Therapeutics Inc.</a> surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n</p>\n<p>\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n</p>\n<p>\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n</p>\n<p>\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n</p>\n<p>\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2022 12:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","HARP":"Harpoon Therapeutics Inc.","BK4007":"制药","CRCT":"Cricut, Inc.","TERN":"Terns Pharmaceuticals, Inc.","BK4191":"家用电器"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2291146287","content_text":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n\n\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n\n\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n\n\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n\n\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n\n\n \n\n\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2022 12:52 ET (17:52 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9915528738,"gmtCreate":1665076334724,"gmtModify":1676537553407,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9915528738","repostId":"2273255383","repostType":2,"repost":{"id":"2273255383","kind":"highlight","pubTimestamp":1665067995,"share":"https://ttm.financial/m/news/2273255383?lang=&edition=fundamental","pubTime":"2022-10-06 22:53","market":"fut","language":"en","title":"There’s a ‘Battery’ of Reasons to Consider Investing in the Atlis Motor Vehicles IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2273255383","media":"InvestorPlace","summary":"Atlis Motor Vehicles (AMV) recently had its initial public offering (IPO), and the share price veere","content":"<html><body><div>\n<div>\n<ul>\n<li><strong>Atlis Motor Vehicles</strong> (<span><strong><u>AMV</u></strong></span>) recently had its initial public offering (<strong>IPO</strong>), and the share price veered wildly in both directions.</li>\n<li>Innovative products could propel Atlis to the forefront of the clean-energy market.</li>\n<li>Risk-tolerant investors might consider a tiny position in AMV stock.</li>\n</ul>\n</div>\n<div></div>\n<figure>\n<div>\n<img height=\"432\" sizes=\"(max-width: 768px) 100vw, 768px\" src=\"https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-768x432.jpg\" srcset=\"https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-768x432.jpg 768w, https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-300x169.jpg 300w, https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-1024x576.jpg 1024w, https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-1536x864.jpg 1536w, https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-200x113.jpg 200w, https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-400x225.jpg 400w, https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-116x65.jpg 116w, https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-100x56.jpg 100w, https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-89x50.jpg 89w, https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600-78x44.jpg 78w, https://investorplace.com/wp-content/uploads/2022/05/electric-vehicle-evs-1600.jpg 1600w\" width=\"768\"/> </div>\n<figcaption>\n<p>Source: Ilija Erceg / Shutterstock</p>\n</figcaption>\n</figure>\n<div>\n<p>Arizona-based <strong>Atlis Motor Vehicles</strong> (NASDAQ:<strong>AMV</strong>) is a truly unique clean-energy business. The company’s investors went on a rollercoaster ride after Atlis’ initial public offering (<strong>IPO</strong>). However, fearful traders should take a close look at Atlis Motor Vehicles’ product lineup. After assessing the risk-to-reward profile, you might actually end up buying a few shares of AMV stock.</p>\n<p>Right now, you might be thinking that there are already enough electric vehicle (EV) startups out there. Who needs another one in an already competitive field?</p>\n<p>That’s a valid concern, but hear me out. Despite the company’s name, Atlis Motor Vehicles doesn’t only focus on developing and producing full vehicles. As we’ll discover, Atlis’ business model is broader than you might expect, and prospective investors should find a host of reasons to consider an early stage stake.</p>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n</div>\n<h2>What’s the Scoop With AMV Stock?</h2>\n<p>Let’s start at the beginning. Mark Hanchett founded Atlis Motor Vehicles in 2016, and the company began its operations in 2018. Atlis’ purpose for the IPO was to “continue to scale operations to produce state-of-the-art batteries, platforms and pickups needed to advance the work truck market,” according to Hanchett.</p>\n<p>AMV stock started trading publicly on the <strong>Nasdaq</strong> exchange on Sept. 17. This IPO took place through a Registration A process, which brings private shares to the public market; Hanchett called the listing “an IPO lite.”</p>\n<p>Yet, there was nothing “lite” about the post-IPO price action of the stock. As <em>InvestorPlace</em> contributor Dana Blankenhorn observed, Atlis shares that opened at $27.50 on Sept. 27 and closed at $82.12 on that day, and then rocketed to $250 early on Sept. 28.</p>\n<p>Fast forward to the last day of September, and AMV stock was all the way down to $24. That’s right — the spectacular gains evaporated. It’s a painful lesson in the value of risk management — and the reason why I’m only encouraging traders to consider a very small position size.</p>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n</div>\n<h2>Focus on Atlis’ Products, Not Its Financials</h2>\n<p>If you’re obsessed with top- and bottom-line figures like I am, then you might be bothered by Atlis Motor Vehicles’ recently filed Form 10-Q. To put it politely, the company is what you might call “pre-revenue.”</p>\n<p>Okay, let’s just go ahead and say it: Atlis has no revenue and no earnings. This might be a deal-breaker for some folks, and I fully understand that. Yet, before you abandon AMV stock altogether, consider giving the company a closer look.</p>\n<p>With 30 patent applications and a vertically integrated business model, Hanchett and Atlis Motor Vehicles clearly want to be a different kind of clean-energy business. By “vertically integrated,” I mean that company seeks to “own” the end-to-end business cycle, from production to sales, maintenance and much more.</p>\n<p>The real selling point here, though, is Atlis’ products. There are three primary products in development or production. First, there’s the ATLIS Energy EV battery, which fully charges in just 15 minutes and has a “million-mile pack life.”</p>\n<p>Next is the XP Platform, a plug-and-play skateboard-style EV platform containing four independently controlled electric motors. Finally, Atlis has the XP Pickup, a powerful electric truck featuring a 15-minute full-charge time, a 500-mile range and 35,000 pounds of towing capacity.</p>\n<h2>What You Can Do Now</h2>\n<p>Whether it’s trading at $24 or $250, AMV stock is impossible to take your eyes off of. It’s a fast mover for risk-tolerant investors — and it’s really only meant for tiny position sizes.</p>\n<p>That said, feel free to explore Atlis Motor Vehicles’ audacious product lineup. Even a pre-revenue company like Atlis can disrupt an industry — and maybe create a new one for future-facing EV enthusiasts.</p>\n<p><span><i>On the date of publication, David Moadel</i></span><i> did not have (either directly or indirectly) any positions in the securities mentioned in this article. </i><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>\n<div>\n<p>David Moadel has provided compelling content – and crossed the occasional line – on behalf of Motley Fool, Crush the Street, Market Realist, TalkMarkets, TipRanks, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.</p>\n</div>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n</div>\n</div>\n<div>\n<div hidden=\"true\">\n<div>\n<svg fill=\"none\" height=\"32\" viewbox=\"0 0 261 32\" width=\"261\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M38.8652 7.49652H42.2492V25.7517H38.8652V7.49652ZM60.0112 7.49652H63.3142V25.7517H60.0921L50.9278 13.1733V25.7517H47.6248V7.49652H50.8469L60.0112 20.0749V7.49652ZM66.5201 7.49652H70.2279L75.4578 21.8955L80.7685 7.49652H84.3144L77.1417 25.7517H73.5957L66.5201 7.49652ZM87.4232 7.49652H100.457V10.5418H90.8072V15.0601H99.5019V18.1054H90.8072V22.7064H100.781V25.7517H87.4232V7.49652ZM113.637 10.8563C112.666 10.5253 111.872 10.3598 111.063 10.3598C110.253 10.3598 109.622 10.5253 109.136 10.8563C108.65 11.1873 108.407 11.601 108.407 12.1803C108.407 12.6768 108.569 13.0906 108.893 13.4216C109.217 13.7526 109.622 14.0009 110.188 14.2491C110.674 14.4974 111.403 14.7456 112.196 14.9939C113.41 15.3249 114.366 15.7387 115.175 16.0697C115.985 16.4007 116.616 16.98 117.183 17.7082C117.75 18.453 117.993 19.3467 117.993 20.5052C117.993 21.6638 117.669 22.5575 117.102 23.385C116.535 24.2125 115.742 24.858 114.689 25.2718C113.637 25.6855 112.52 25.9338 111.144 25.9338C109.767 25.9338 108.407 25.6855 107.047 25.1063C105.752 24.6098 104.554 23.865 103.582 22.9713L105.023 20.0087C105.914 20.8362 106.95 21.4817 108.083 21.9782C109.217 22.4747 110.253 22.723 111.225 22.723C112.196 22.723 112.908 22.5575 113.475 22.1437C114.042 21.73 114.285 21.2334 114.285 20.588C114.285 20.0915 114.123 19.5949 113.799 19.2639C113.475 18.9329 113.07 18.6847 112.504 18.4364C112.018 18.1882 111.289 18.0226 110.415 17.6916C109.201 17.3606 108.245 16.9469 107.436 16.6159C106.626 16.2848 105.995 15.7056 105.509 15.0601C104.942 14.3153 104.699 13.4216 104.699 12.2631C104.699 11.1873 104.942 10.2936 105.509 9.46603C106.076 8.6385 106.869 8.07578 107.841 7.66202C108.893 7.24826 110.01 7 111.386 7C112.52 7 113.718 7.16551 114.851 7.49652C115.985 7.82753 117.021 8.32404 117.912 8.88676L116.471 12.1803C115.499 11.6838 114.609 11.27 113.637 10.8563ZM120.146 7.49652H134.702V10.6246H129.148V25.7517H125.683V10.608H120.13V7.49652H120.146ZM149.987 8.473C151.428 9.30052 152.561 10.4425 153.452 11.8493C154.261 13.2395 154.747 14.8946 154.747 16.6159C154.747 18.3371 154.342 19.9094 153.452 21.3824C152.642 22.7726 151.444 23.9312 149.987 24.7587C148.546 25.5862 146.926 26 145.162 26C143.397 26 141.778 25.5862 140.337 24.7587C138.896 23.9312 137.762 22.7892 136.872 21.3824C136.062 19.9922 135.576 18.3371 135.576 16.6159C135.576 14.8946 135.981 13.3223 136.872 11.8493C137.681 10.4591 138.879 9.30052 140.337 8.473C141.794 7.64547 143.397 7.23171 145.162 7.23171C146.926 7.23171 148.546 7.66202 149.987 8.473ZM142.182 11.1873C141.211 11.7666 140.499 12.5113 139.932 13.4051C139.365 14.3981 139.122 15.3746 139.122 16.5331C139.122 17.6916 139.365 18.7509 139.932 19.6611C140.499 20.6542 141.227 21.3824 142.182 21.9617C143.073 22.5409 144.109 22.7892 145.243 22.7892C146.295 22.7892 147.331 22.5409 148.222 21.9617C149.112 21.3824 149.825 20.6376 150.391 19.6611C150.958 18.6681 151.201 17.6916 151.201 16.5331C151.201 15.3746 150.958 14.3153 150.391 13.4051C149.825 12.4948 149.096 11.6838 148.222 11.1873C147.331 10.608 146.295 10.3598 145.243 10.3598C144.109 10.3763 143.073 10.608 142.182 11.1873ZM169.773 25.7517L166.712 20.3232H162.049V25.669H158.665V7.49652H166.065C168.396 7.49652 170.161 8.07578 171.456 9.13502C172.752 10.2108 173.302 11.7666 173.302 13.7361C173.302 15.1263 172.978 16.3676 172.412 17.3606C171.764 18.3537 170.971 19.0819 169.756 19.6611L173.691 25.669H169.756L169.773 25.7517ZM161.968 17.2779H165.984C167.279 17.2779 168.234 17.0296 168.963 16.4503C169.611 15.8711 170.015 15.0601 170.015 13.9016C170.015 12.743 169.692 11.9321 168.963 11.4355C168.315 10.8563 167.279 10.608 165.984 10.608H161.968V17.2779ZM190.757 8.90331C191.971 9.97909 192.521 11.4521 192.521 13.3389C192.521 15.3084 191.874 16.8807 190.757 17.9399C189.542 19.0157 187.858 19.5784 185.608 19.5784H180.783V25.5035H179.018V7.34756H185.608C187.777 7.34756 189.542 7.92683 190.757 8.90331ZM189.461 16.8807C190.352 16.0531 190.821 14.9939 190.821 13.4216C190.821 11.9486 190.336 10.8728 189.461 10.0453C188.571 9.21777 187.211 8.88676 185.527 8.88676H180.783V18.0226H185.527C187.211 18.0392 188.506 17.7082 189.461 16.8807ZM197.023 7.34756H198.787V23.9643H206.673V25.6028H197.104V7.34756H197.023ZM224.516 25.6028L222.427 20.7535H212.534L210.445 25.6028H208.599L216.647 7.43031H218.492L226.54 25.6028H224.516ZM213.182 19.115H221.714L217.456 9.25087L213.182 19.115ZM240.286 9.39983C239.315 8.98606 238.359 8.82056 237.388 8.82056C236.028 8.82056 234.732 9.15157 233.599 9.81359C232.466 10.4756 231.51 11.3693 230.863 12.6106C230.215 13.7692 229.81 15.0767 229.81 16.4835C229.81 17.8737 230.134 19.115 230.863 20.3563C231.51 21.5148 232.466 22.4085 233.599 23.1533C234.732 23.8153 236.011 24.2291 237.388 24.2291C238.359 24.2291 239.315 24.0636 240.286 23.6498C241.257 23.2361 242.051 22.7395 242.779 22.0113L243.832 23.1699C242.941 23.9974 241.905 24.6429 240.772 25.1394C239.638 25.6359 238.44 25.8841 237.307 25.8841C235.623 25.8841 234.085 25.4704 232.644 24.6429C231.203 23.8153 230.15 22.6733 229.26 21.2666C228.45 19.8763 228.045 18.304 228.045 16.5828C228.045 14.8615 228.45 13.372 229.341 11.9817C230.15 10.5915 231.267 9.43293 232.725 8.6054C234.166 7.77788 235.704 7.36411 237.388 7.36411C238.602 7.36411 239.719 7.61237 240.853 8.02613C241.986 8.52265 242.941 9.10192 243.832 9.91289L242.779 11.1376C242.051 10.3929 241.241 9.81359 240.286 9.39983ZM248.641 7.34756H260.541V8.98606H250.406V15.4904H259.489V17.1289H250.406V23.9477H260.865V25.5862H248.641V7.34756Z\" fill=\"#212121\"></path>\n<path d=\"M31.3505 14.3755C31.3667 14.6507 31.3829 15.1201 31.2857 15.1687C31.1077 15.1201 30.9458 13.5337 31.1077 13.4365H31.1239C31.2534 13.4689 31.3343 14.0355 31.3505 14.3755Z\" fill=\"#00A000\"></path>\n<path d=\"M16.959 13.1775C16.7485 15.4763 13.8346 16.3343 12.4424 14.505C11.3092 13.0156 12.1996 10.6036 14.4659 10.4902C16.3438 10.6036 17.0561 12.1253 16.959 13.1775Z\" fill=\"#00A000\"></path>\n<path d=\"M14.1103 18.034C14.0456 18.7949 13.4952 20.1223 11.8116 20.2195C9.41565 20.09 8.65479 17.176 10.1441 15.8C10.7269 15.282 11.3421 15.2496 11.6497 15.2334C13.4952 15.3305 14.2075 16.9332 14.1103 18.034Z\" fill=\"#00A000\"></path>\n<path d=\"M21.4764 15.9942C21.4116 16.7875 20.8288 18.1797 19.1128 18.2768C16.555 18.1473 15.9075 15.1686 17.5749 13.7602C18.1901 13.2422 18.8052 13.2098 19.1128 13.1936C21.0069 13.3069 21.5735 14.9743 21.4764 15.9942Z\" fill=\"#00A000\"></path>\n<path d=\"M18.7565 20.6727C18.4004 22.7773 15.6969 23.4248 14.4504 21.7088C13.4952 20.3975 14.1104 18.1311 16.4739 18.0178C18.3356 18.115 18.9184 19.6205 18.7565 20.6727Z\" fill=\"#00A000\"></path>\n<path d=\"M12.1507 10.555C12.0373 11.2349 11.4384 12.4005 9.98138 12.4976C7.90925 12.3843 7.89306 10.0046 9.1072 8.90376C9.68999 8.38572 10.2242 8.35335 10.4832 8.33716C11.9726 8.4181 12.2963 9.74556 12.1507 10.555Z\" fill=\"#00A000\"></path>\n<path d=\"M18.9993 8.758C19.0155 10.4578 16.8462 11.2187 15.5349 9.97214C14.3532 8.85513 14.9521 6.76681 16.8948 6.66968C18.4165 6.76681 18.9831 7.99714 18.9993 8.758Z\" fill=\"#00A000\"></path>\n<path d=\"M23.2892 11.2836C23.3864 13.0157 21.6056 13.8737 20.2458 12.7405C18.805 11.5264 19.2259 9.19524 20.9095 9.01717C20.9581 9.01717 21.039 9.01717 21.1038 9.00098C22.6093 9.09811 23.2407 10.4579 23.2892 11.2836Z\" fill=\"#00A000\"></path>\n<path d=\"M9.34996 15.1687C9.28521 15.8972 8.79955 17.1599 7.4559 17.2409C5.44853 17.1114 5.10857 14.2136 6.53316 13.0642C6.95406 12.7405 7.31021 12.7081 7.55304 12.6919C8.86431 12.7728 9.46328 14.0355 9.34996 15.1687Z\" fill=\"#00A000\"></path>\n<path d=\"M25.0365 18.6978C24.6642 20.608 22.6406 21.3203 21.7017 19.8634C20.8599 18.5521 21.6369 16.3343 23.4015 16.2209C24.8422 16.3181 25.2308 17.7265 25.0365 18.6978Z\" fill=\"#00A000\"></path>\n<path d=\"M11.6007 22.4698C11.633 23.9267 10.1437 24.7847 8.80003 23.603C7.47257 22.4212 7.7154 20.3976 9.22093 20.2196C9.2695 20.2196 9.35044 20.2196 9.4152 20.2034C10.7265 20.2843 11.5683 21.4337 11.6007 22.4698Z\" fill=\"#00A000\"></path>\n<path d=\"M15.8267 24.7199C15.7781 25.2218 15.341 26.1769 14.1269 26.2417C12.4433 26.1607 11.4882 24.1857 12.6052 23.1335C13.0585 22.7126 13.5765 22.6964 13.8031 22.6802C15.1953 22.7449 15.94 23.781 15.8267 24.7199Z\" fill=\"#00A000\"></path>\n<path d=\"M22.1549 23.101C21.6044 24.6713 19.5485 25.3835 18.7715 23.8942C18.1563 22.7286 19.0628 20.9641 20.7303 20.8669C21.8797 20.8831 22.5758 21.9354 22.1549 23.101Z\" fill=\"#00A000\"></path>\n<path d=\"M14.6774 6.50773C14.5965 7.00958 14.0946 7.9647 12.7995 8.02946C11.1807 7.93233 10.9702 6.31347 12.0225 5.32597C12.5567 4.82413 13.0747 4.80794 13.2852 4.79175C14.4184 4.8565 14.7907 5.82781 14.6774 6.50773Z\" fill=\"#00A000\"></path>\n<path d=\"M7.18189 19.9604C7.19808 20.1223 7.26284 21.5631 6.06488 21.6602C4.41365 21.5469 3.71755 18.8758 4.75361 18.0016C5.01263 17.7912 5.25546 17.775 5.41734 17.7588C6.53435 17.8397 7.11714 19.0862 7.18189 19.9604Z\" fill=\"#00A000\"></path>\n<path d=\"M26.9959 13.906C27.0282 15.4601 25.7655 16.3019 24.7457 15.4115C23.5477 14.3593 23.7096 11.8177 25.3123 11.7043C26.3645 11.7691 26.9635 12.8861 26.9959 13.906Z\" fill=\"#00A000\"></path>\n<path d=\"M18.9988 26.7921C18.9826 26.8407 18.5455 27.8929 17.3961 27.9577C16.182 27.8767 15.7611 26.436 16.7 25.5941C17.1695 25.1732 17.6551 25.1571 17.8656 25.1409C19.0635 25.2218 19.2416 26.1446 18.9988 26.7921Z\" fill=\"#00A000\"></path>\n<path d=\"M20.0999 4.92117C20.1808 5.32589 20.0837 6.11913 19.08 6.16769C17.6392 6.08675 16.9755 4.53265 17.7525 3.77179C18.0116 3.52896 18.303 3.51277 18.4325 3.49658C19.3228 3.56134 19.9704 4.37076 20.0999 4.92117Z\" fill=\"#00A000\"></path>\n<path d=\"M8.33073 8.11044C8.15266 8.61229 7.55368 9.55122 6.58237 9.61598C5.33585 9.51884 5.57868 7.80286 6.6795 6.86392C7.16515 6.44302 7.53749 6.42683 7.68319 6.41064C8.54118 6.4754 8.58975 7.44671 8.33073 8.11044Z\" fill=\"#00A000\"></path>\n<path d=\"M5.43276 12.449C5.30325 13.0317 4.86616 14.0516 3.97579 14.1164C2.6807 14.0031 2.8264 11.6557 3.89485 10.7492C4.20243 10.4901 4.42907 10.474 4.59095 10.4578C5.40038 10.5387 5.62702 11.5424 5.43276 12.449Z\" fill=\"#00A000\"></path>\n<path d=\"M24.1468 6.88001C24.5029 7.98083 23.6773 8.66075 22.6251 8.11034C21.4109 7.4628 21.0224 5.58493 22.0423 5.30972C22.107 5.29353 22.2042 5.29353 22.2689 5.27734C23.224 5.3421 23.9363 6.24866 24.1468 6.88001Z\" fill=\"#00A000\"></path>\n<path d=\"M10.0796 26.3387C10.0958 26.3873 10.4196 27.4395 9.5454 27.4881C8.34745 27.4233 7.08474 25.6264 7.78085 24.9789C7.94273 24.817 8.15318 24.8008 8.28269 24.8008C9.20544 24.8493 9.88536 25.7235 10.0796 26.3387Z\" fill=\"#00A000\"></path>\n<path d=\"M27.3692 21.3364C26.916 22.5991 25.5885 23.3438 25.1514 22.3077C24.7143 21.304 25.5237 19.4747 26.7055 19.3938C27.6283 19.4747 27.6444 20.5756 27.3692 21.3364Z\" fill=\"#00A000\"></path>\n<path d=\"M24.245 25.2864C23.5975 26.4034 22.2053 26.9862 21.9463 26.0311C21.7034 25.1569 22.6586 23.7323 23.7917 23.6514C24.6336 23.7161 24.6821 24.5579 24.245 25.2864Z\" fill=\"#00A000\"></path>\n<path d=\"M13.8031 28.1518C13.9003 29.0098 13.0909 29.4631 12.1519 28.7184C11.1644 27.9576 11.3101 26.9377 12.1519 26.8406C12.1843 26.8406 12.2329 26.8406 12.2814 26.8406C13.1394 26.873 13.7384 27.5529 13.8031 28.1518Z\" fill=\"#00A000\"></path>\n<path d=\"M16.4094 3.23778C16.3446 4.22528 14.9848 4.50049 14.4182 3.83676C13.9002 3.20541 14.4668 2.18553 15.3571 2.13696C16.0047 2.15315 16.4418 2.71975 16.4094 3.23778Z\" fill=\"#00A000\"></path>\n<path d=\"M11.3909 4.41948C10.8891 5.55268 9.52923 5.95739 9.18927 5.27747C8.8655 4.59756 9.95013 3.31866 10.9053 3.25391C11.5042 3.25391 11.6337 3.85288 11.3909 4.41948Z\" fill=\"#00A000\"></path>\n<path d=\"M3.3601 17.1921C3.37629 18.4063 2.74494 19.0862 2.12977 18.5034C1.32034 17.7264 1.30416 15.3466 2.34022 15.2495C3.06871 15.3305 3.34391 16.4798 3.3601 17.1921Z\" fill=\"#00A000\"></path>\n<path d=\"M27.6917 9.24369C27.9993 10.2798 27.4812 10.9435 26.688 10.5226C25.6519 9.97217 25.1177 7.91622 25.9433 7.64102C25.9919 7.62483 26.0728 7.62483 26.1214 7.60864C26.8984 7.6734 27.4974 8.59614 27.6917 9.24369Z\" fill=\"#00A000\"></path>\n<path d=\"M29.5543 16.6256C29.4409 17.9045 28.6153 18.6006 28.0649 17.8883C27.4012 17.0303 27.6764 14.8287 28.6801 14.7153C29.3924 14.7801 29.619 15.8809 29.5543 16.6256Z\" fill=\"#00A000\"></path>\n<path d=\"M6.01558 24.218C6.03177 24.2666 6.43648 25.3674 5.72419 25.4483C4.68812 25.3674 3.49017 23.3924 4.10533 22.7772C4.20246 22.6801 4.31578 22.6639 4.41292 22.6477C5.10902 22.6963 5.75656 23.4895 6.01558 24.218Z\" fill=\"#00A000\"></path>\n<path d=\"M16.5051 29.5441C16.2946 30.2887 15.2909 30.5154 14.87 29.706C14.611 29.2041 14.8862 28.6213 15.6633 28.5728C16.3432 28.6051 16.6346 29.0908 16.5051 29.5441Z\" fill=\"#00A000\"></path>\n<path d=\"M20.7967 28.4756C20.5538 28.7831 19.9711 29.2688 19.4206 29.285C18.7407 29.2364 18.9512 28.2813 19.6311 27.7147C20.0682 27.3424 20.4405 27.3262 20.57 27.3262C21.2176 27.3747 21.2176 27.9575 20.7967 28.4756Z\" fill=\"#00A000\"></path>\n<path d=\"M19.8739 2.15321C20.0682 2.41223 20.1815 2.81694 19.6797 2.84932C18.8217 2.80076 18.1741 1.7485 18.5141 1.48948C18.5626 1.44092 18.6274 1.44092 18.6922 1.44092C19.0969 1.45711 19.6311 1.82944 19.8739 2.15321Z\" fill=\"#00A000\"></path>\n<path d=\"M13.8509 1.66741C13.5433 2.29876 12.653 2.54159 12.4749 2.15307C12.313 1.74835 13.09 1.08462 13.6243 1.05225C13.9642 1.05225 13.9966 1.37602 13.8509 1.66741Z\" fill=\"#00A000\"></path>\n<path d=\"M6.12972 5.87644C5.54693 6.75062 4.76988 7.07439 4.67275 6.6373C4.55943 6.11927 5.57931 4.77562 6.2916 4.72705C6.76107 4.77562 6.38874 5.48791 6.12972 5.87644Z\" fill=\"#00A000\"></path>\n<path d=\"M23.3061 3.67478C23.5165 3.93379 23.7594 4.45183 23.2413 4.4842C22.3348 4.40326 21.4282 3.0758 21.7196 2.80059C21.7682 2.75203 21.8329 2.75203 21.8977 2.73584C22.351 2.76822 22.9661 3.23768 23.3061 3.67478Z\" fill=\"#00A000\"></path>\n<path d=\"M2.97199 9.87496C2.92343 9.98828 2.51871 10.9596 2.00068 11.0082C1.33695 10.911 2.00068 9.01696 2.69679 8.56368C2.81011 8.48274 2.87486 8.48274 2.93962 8.46655C3.34433 8.53131 3.18244 9.34073 2.97199 9.87496Z\" fill=\"#00A000\"></path>\n<path d=\"M30.3314 11.7206C30.4124 12.1253 30.4448 12.8861 30.0401 12.9347C29.2792 12.8376 28.8421 10.7007 29.2792 10.3284C29.3278 10.2798 29.3925 10.2798 29.4249 10.2798C29.862 10.3445 30.2181 11.154 30.3314 11.7206Z\" fill=\"#00A000\"></path>\n<path d=\"M2.47043 21.7897C2.66469 22.421 2.63231 23.0362 2.27616 22.8743C1.61243 22.5829 0.916326 20.5432 1.43436 20.3975H1.48293C1.88764 20.446 2.30854 21.2393 2.47043 21.7897Z\" fill=\"#00A000\"></path>\n<path d=\"M28.3552 23.8296C27.9343 24.5581 27.2705 25.0923 27.141 24.6714C26.9629 24.121 27.8209 22.5831 28.4523 22.5183C28.8246 22.5669 28.6951 23.2306 28.3552 23.8296Z\" fill=\"#00A000\"></path>\n<path d=\"M10.1606 29.544C10.4035 29.8031 10.5977 30.1268 10.3225 30.1268C9.7883 30.143 8.37989 29.1555 8.63891 28.7994C8.67129 28.7508 8.73604 28.7346 8.8008 28.7346C9.31883 28.767 9.9178 29.285 10.1606 29.544Z\" fill=\"#00A000\"></path>\n<path d=\"M24.9563 27.4396C24.7296 27.6987 24.1792 28.1681 23.7583 28.2005C23.305 28.1519 23.9202 27.213 24.5192 26.7435C24.9239 26.4198 25.1505 26.4036 25.2315 26.4036C25.62 26.4521 25.3933 26.9702 24.9563 27.4396Z\" fill=\"#00A000\"></path>\n<path d=\"M13.1878 30.6613C13.2849 30.7746 13.5115 31.0498 13.2525 31.0822C12.7183 31.0822 11.6822 30.4346 11.9413 30.1756C11.9898 30.127 12.0708 30.1108 12.1193 30.1108C12.5564 30.1108 13.0097 30.467 13.1878 30.6613Z\" fill=\"#00A000\"></path>\n<path d=\"M17.7192 30.7906C17.5735 30.9201 17.2497 31.1305 16.9745 31.1467C16.6346 31.1305 16.8612 30.661 17.1202 30.4344C17.2983 30.2887 17.4764 30.2078 17.6868 30.2078C18.0592 30.2401 17.9944 30.5315 17.7192 30.7906Z\" fill=\"#00A000\"></path>\n<path d=\"M9.64113 2.73581C9.544 2.83294 8.99359 3.35097 8.52412 3.38335C8.16798 3.35097 8.39462 2.94626 8.81552 2.59011C9.04216 2.39585 9.56019 2.02351 9.93253 2.00732C10.3211 2.0397 9.67351 2.70343 9.64113 2.73581Z\" fill=\"#00A000\"></path>\n<path d=\"M16.9275 0.890291C17.0894 1.23025 16.7332 1.40832 16.3933 1.27882C15.94 1.10074 15.9076 0.598897 16.1666 0.469389C16.2152 0.4532 16.2476 0.437012 16.2961 0.437012C16.5552 0.4532 16.8304 0.67984 16.9275 0.890291Z\" fill=\"#00A000\"></path>\n<path d=\"M26.6083 5.5365C26.9644 6.03834 26.9806 6.42687 26.6407 6.3783C26.0741 6.29736 25.0056 4.88896 25.2808 4.59756C25.3132 4.56519 25.3618 4.56519 25.3941 4.56519C25.7989 4.59756 26.3493 5.14797 26.6083 5.5365Z\" fill=\"#00A000\"></path>\n<path d=\"M0.689784 14.2135C0.641218 14.6182 0.51171 15.3143 0.252693 15.3629C-0.232963 15.2658 0.0746191 13.1127 0.39839 12.9023L0.463144 12.8699C0.738349 12.9184 0.754538 13.7279 0.689784 14.2135Z\" fill=\"#00A000\"></path>\n<path d=\"M30.816 19.4909C30.6217 20.2517 30.2656 20.7374 30.1037 20.446C29.877 19.9927 30.2656 18.2767 30.7189 18.1958C30.9779 18.2444 30.9617 18.9081 30.816 19.4909Z\" fill=\"#00A000\"></path>\n<path d=\"M6.7129 27.6823C7.02048 28.0384 7.21474 28.3784 6.93954 28.346C6.38913 28.2651 5.17499 27.0024 5.46638 26.8243L5.54732 26.8081C5.91966 26.8567 6.45388 27.3747 6.7129 27.6823Z\" fill=\"#00A000\"></path>\n<path d=\"M21.0704 29.8516C20.6171 30.1592 20.002 30.402 20.002 30.2239C20.0181 30.0458 20.8923 29.2526 21.4427 29.2202C21.7179 29.2526 21.4751 29.5278 21.2808 29.6897C21.2485 29.7059 21.1675 29.7868 21.0704 29.8516Z\" fill=\"#00A000\"></path>\n<path d=\"M15.2925 31.163C15.3735 31.3249 15.3249 31.4544 14.9849 31.3573C14.6612 31.2601 14.4993 31.0497 14.6612 30.9525L14.7583 30.9202C15.0173 30.8716 15.2116 31.0173 15.2925 31.163Z\" fill=\"#00A000\"></path>\n<path d=\"M12.8303 0.469616C12.3932 0.744822 12.0695 0.809576 12.1018 0.712445C12.1342 0.534371 12.9113 0.194411 13.1541 0.178223C13.1865 0.178223 13.235 0.178223 13.1217 0.275354C13.057 0.32392 12.9436 0.404862 12.8303 0.469616Z\" fill=\"#00A000\"></path>\n<path d=\"M15.3237 0.161885C15.2913 0.22664 15.178 0.339959 14.9999 0.356148C14.8542 0.339959 14.8704 0.242828 14.9676 0.145697C15.0485 0.0809427 15.1942 0 15.2913 0C15.4208 0.0161885 15.3237 0.161885 15.3237 0.161885Z\" fill=\"#00A000\"></path>\n<path d=\"M0.608603 18.9245C0.721923 19.4587 0.721923 19.8148 0.64098 19.7663C0.430529 19.653 0.0743813 17.8884 0.236267 17.8398C0.333398 17.8884 0.495283 18.4226 0.608603 18.9245Z\" fill=\"#00A000\"></path>\n<path d=\"M29.3427 7.9001C29.537 8.24006 29.6503 8.58002 29.4884 8.53145C29.2132 8.45051 28.4847 7.20399 28.679 7.12305H28.6952C28.8571 7.17161 29.1485 7.56014 29.3427 7.9001Z\" fill=\"#00A000\"></path>\n<path d=\"M3.61909 25.3512C3.66766 25.4159 4.03999 25.934 3.92667 25.9663C3.66766 25.9178 2.68015 24.6389 2.84204 24.5417H2.85823C3.00392 24.5903 3.40864 25.0598 3.61909 25.3512Z\" fill=\"#00A000\"></path>\n<path d=\"M18.1414 0.259053C18.3519 0.339996 18.449 0.40475 18.4166 0.420939C18.3357 0.485693 17.4939 0.194299 17.4453 0.113357L17.4615 0.097168C17.5748 0.113357 17.8986 0.178111 18.1414 0.259053Z\" fill=\"#00A000\"></path>\n<path d=\"M2.43813 7.4629C2.35719 7.57622 2.11436 7.96474 2.01723 8.01331C1.87153 7.96474 2.60002 6.88011 2.71334 6.83154H2.72952C2.81047 6.86392 2.4867 7.39814 2.43813 7.4629Z\" fill=\"#00A000\"></path>\n<path d=\"M5.67515 3.78798C5.319 4.12794 5.09236 4.25745 5.07617 4.1765C5.07617 4.03081 5.82084 3.31851 6.06367 3.28613C6.17699 3.28613 5.90179 3.57753 5.67515 3.78798Z\" fill=\"#00A000\"></path>\n<path d=\"M21.0058 1.03617C21.2648 1.18187 21.3944 1.29519 21.3134 1.31138C21.1515 1.34376 20.0993 0.777157 20.1802 0.712402H20.2126C20.3745 0.728591 20.763 0.890476 21.0058 1.03617Z\" fill=\"#00A000\"></path>\n<path d=\"M24.6005 2.81684C24.8919 3.04348 25.0376 3.22156 24.9243 3.22156C24.7139 3.23775 23.4835 2.33119 23.613 2.25024H23.6454C23.8721 2.29881 24.3091 2.5902 24.6005 2.81684Z\" fill=\"#00A000\"></path>\n<path d=\"M9.69156 1.31126C9.57824 1.37602 9.23828 1.55409 9.18971 1.52171C9.17352 1.42458 9.9182 1.06843 10.0801 1.05225C10.0963 1.10081 9.75631 1.27889 9.69156 1.31126Z\" fill=\"#00A000\"></path>\n</svg>\n<img src=\"https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif\"/>\n</div>\n<div>\n<label>\n<span></span>\n</label>\n<h3></h3>\n<div></div>\n<div>\n<form method=\"post\">\n<input type=\"hidden\" value=\"\"/>\n<input type=\"hidden\" value=\"\"/>\n<input type=\"hidden\" value=\"\"/>\n<input type=\"hidden\" value=\"free\"/>\n<input placeholder=\"Email Address\" required=\"\" type=\"email\" value=\"\"/>\n<button>Submit</button>\n</form>\n</div>\n</div>\n</div>\n</div>\n<div>\n<hr/>\n<p>Article printed from InvestorPlace Media, https://investorplace.com/2022/10/theres-a-battery-of-reasons-to-consider-investing-in-the-atlis-motor-vehicles-ipo/.</p>\n<p>©2022 InvestorPlace Media, LLC</p>\n</div>\n<div>\n</div>\n<div>\n<div>\n<h2>Sponsored Headlines</h2>\n</div>\n<div>\n<ins></ins>\n</div>\n</div>\n<div>\n<div>\n</div>\n</div>\n<div>\n<div>\n<h2>\n\t\t\t\t\tMore from InvestorPlace\t\t\t\t</h2>\n</div>\n<div>\n<div>\n<div>\n<figure>\n<img src=\"https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif\"/>\n</figure>\n</div>\n<div>\n<p>\n\n\t\t\t\t\t\t\t\t\tHot Stocks\t\t\t\t\t\t\t\t\n</p>\n<h3>\n\n\t\t\t\t\t\t\t\tWhy Oct. 7 Is the Next Big Event for Mullen Stock\t\t\t\t\t\t\t\n</h3>\n<div>\n<span hidden=\"\"></span>\n\t\t\t\t\t\t\tBy Louis Navellier and the InvestorPlace Research Staff\n<span>\n\t\t\t\t\t\t\t\tOct 5, 2022\t\t\t\t\t\t\t</span>\n</div>\n</div>\n</div>\n</div>\n<div>\n<div>\n<div>\n<figure>\n<img src=\"https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif\"/>\n</figure>\n</div>\n<div>\n<p>\n\n\t\t\t\t\t\t\t\t\tMarket Analysis\t\t\t\t\t\t\t\t\n</p>\n<h3>\n\n\t\t\t\t\t\t\t\tBad News Pushes Stocks Higher\t\t\t\t\t\t\t\n</h3>\n<div>\n<span hidden=\"\"></span>\n\t\t\t\t\t\t\tBy John Jagerson and Wade Hansen\n<span>\n\t\t\t\t\t\t\t\tOct 4, 2022\t\t\t\t\t\t\t</span>\n</div>\n</div>\n</div>\n</div>\n<div>\n<div>\n<div>\n<figure>\n<img src=\"https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif\"/>\n</figure>\n</div>\n<div>\n<p>\n\n\t\t\t\t\t\t\t\t\tToday's Market\t\t\t\t\t\t\t\t\n</p>\n<h3>\n\n\t\t\t\t\t\t\t\tCarl Icahn Just Made a Big Bet on Twitter (TWTR) Stock\t\t\t\t\t\t\t\n</h3>\n<div>\n<span hidden=\"\"></span>\n\t\t\t\t\t\t\tBy Joel Baglole\n<span>\n\t\t\t\t\t\t\t\tOct 6, 2022\t\t\t\t\t\t\t</span>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>There’s a ‘Battery’ of Reasons to Consider Investing in the Atlis Motor Vehicles IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThere’s a ‘Battery’ of Reasons to Consider Investing in the Atlis Motor Vehicles IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-06 22:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/10/theres-a-battery-of-reasons-to-consider-investing-in-the-atlis-motor-vehicles-ipo/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Atlis Motor Vehicles (AMV) recently had its initial public offering (IPO), and the share price veered wildly in both directions.\nInnovative products could propel Atlis to the forefront of the clean-...</p>\n\n<a href=\"https://investorplace.com/2022/10/theres-a-battery-of-reasons-to-consider-investing-in-the-atlis-motor-vehicles-ipo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPO":"Renaissance IPO ETF","BK4508":"社交媒体","QNETCN":"纳斯达克中美互联网老虎指数","BK4534":"瑞士信贷持仓","TWTR":"Twitter","BK4077":"互动媒体与服务","BK4579":"人工智能","BK4516":"特朗普概念"},"source_url":"https://investorplace.com/2022/10/theres-a-battery-of-reasons-to-consider-investing-in-the-atlis-motor-vehicles-ipo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2273255383","content_text":"Atlis Motor Vehicles (AMV) recently had its initial public offering (IPO), and the share price veered wildly in both directions.\nInnovative products could propel Atlis to the forefront of the clean-energy market.\nRisk-tolerant investors might consider a tiny position in AMV stock.\n\n\n\n\n\n \n\nSource: Ilija Erceg / Shutterstock\n\n\n\nArizona-based Atlis Motor Vehicles (NASDAQ:AMV) is a truly unique clean-energy business. The company’s investors went on a rollercoaster ride after Atlis’ initial public offering (IPO). However, fearful traders should take a close look at Atlis Motor Vehicles’ product lineup. After assessing the risk-to-reward profile, you might actually end up buying a few shares of AMV stock.\nRight now, you might be thinking that there are already enough electric vehicle (EV) startups out there. Who needs another one in an already competitive field?\nThat’s a valid concern, but hear me out. Despite the company’s name, Atlis Motor Vehicles doesn’t only focus on developing and producing full vehicles. As we’ll discover, Atlis’ business model is broader than you might expect, and prospective investors should find a host of reasons to consider an early stage stake.\n\n\n\n\n\n\nWhat’s the Scoop With AMV Stock?\nLet’s start at the beginning. Mark Hanchett founded Atlis Motor Vehicles in 2016, and the company began its operations in 2018. Atlis’ purpose for the IPO was to “continue to scale operations to produce state-of-the-art batteries, platforms and pickups needed to advance the work truck market,” according to Hanchett.\nAMV stock started trading publicly on the Nasdaq exchange on Sept. 17. This IPO took place through a Registration A process, which brings private shares to the public market; Hanchett called the listing “an IPO lite.”\nYet, there was nothing “lite” about the post-IPO price action of the stock. As InvestorPlace contributor Dana Blankenhorn observed, Atlis shares that opened at $27.50 on Sept. 27 and closed at $82.12 on that day, and then rocketed to $250 early on Sept. 28.\nFast forward to the last day of September, and AMV stock was all the way down to $24. That’s right — the spectacular gains evaporated. It’s a painful lesson in the value of risk management — and the reason why I’m only encouraging traders to consider a very small position size.\n\n\n\n\n\n\nFocus on Atlis’ Products, Not Its Financials\nIf you’re obsessed with top- and bottom-line figures like I am, then you might be bothered by Atlis Motor Vehicles’ recently filed Form 10-Q. To put it politely, the company is what you might call “pre-revenue.”\nOkay, let’s just go ahead and say it: Atlis has no revenue and no earnings. This might be a deal-breaker for some folks, and I fully understand that. Yet, before you abandon AMV stock altogether, consider giving the company a closer look.\nWith 30 patent applications and a vertically integrated business model, Hanchett and Atlis Motor Vehicles clearly want to be a different kind of clean-energy business. By “vertically integrated,” I mean that company seeks to “own” the end-to-end business cycle, from production to sales, maintenance and much more.\nThe real selling point here, though, is Atlis’ products. There are three primary products in development or production. First, there’s the ATLIS Energy EV battery, which fully charges in just 15 minutes and has a “million-mile pack life.”\nNext is the XP Platform, a plug-and-play skateboard-style EV platform containing four independently controlled electric motors. Finally, Atlis has the XP Pickup, a powerful electric truck featuring a 15-minute full-charge time, a 500-mile range and 35,000 pounds of towing capacity.\nWhat You Can Do Now\nWhether it’s trading at $24 or $250, AMV stock is impossible to take your eyes off of. It’s a fast mover for risk-tolerant investors — and it’s really only meant for tiny position sizes.\nThat said, feel free to explore Atlis Motor Vehicles’ audacious product lineup. Even a pre-revenue company like Atlis can disrupt an industry — and maybe create a new one for future-facing EV enthusiasts.\nOn the date of publication, David Moadel did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\n\nDavid Moadel has provided compelling content – and crossed the occasional line – on behalf of Motley Fool, Crush the Street, Market Realist, TalkMarkets, TipRanks, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2022/10/theres-a-battery-of-reasons-to-consider-investing-in-the-atlis-motor-vehicles-ipo/.\n©2022 InvestorPlace Media, LLC\n\n\n\n\n\nSponsored Headlines\n\n\n\n\n\n\n\n\n\n\n\n\n\t\t\t\t\tMore from InvestorPlace\t\t\t\t\n\n\n\n\n\n\n\n\n\n\n\n\t\t\t\t\t\t\t\t\tHot Stocks\t\t\t\t\t\t\t\t\n\n\n\n\t\t\t\t\t\t\t\tWhy Oct. 7 Is the Next Big Event for Mullen Stock\t\t\t\t\t\t\t\n\n\n\n\t\t\t\t\t\t\tBy Louis Navellier and the InvestorPlace Research Staff\n\n\t\t\t\t\t\t\t\tOct 5, 2022\t\t\t\t\t\t\t\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\t\t\t\t\t\t\t\t\tMarket Analysis\t\t\t\t\t\t\t\t\n\n\n\n\t\t\t\t\t\t\t\tBad News Pushes Stocks Higher\t\t\t\t\t\t\t\n\n\n\n\t\t\t\t\t\t\tBy John Jagerson and Wade Hansen\n\n\t\t\t\t\t\t\t\tOct 4, 2022\t\t\t\t\t\t\t\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\t\t\t\t\t\t\t\t\tToday's Market\t\t\t\t\t\t\t\t\n\n\n\n\t\t\t\t\t\t\t\tCarl Icahn Just Made a Big Bet on Twitter (TWTR) Stock\t\t\t\t\t\t\t\n\n\n\n\t\t\t\t\t\t\tBy Joel Baglole\n\n\t\t\t\t\t\t\t\tOct 6, 2022","news_type":1},"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9919401161,"gmtCreate":1663833732953,"gmtModify":1676537346296,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍","listText":"Keep going 👍","text":"Keep going 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9919401161","repostId":"2269148689","repostType":2,"repost":{"id":"2269148689","kind":"highlight","pubTimestamp":1663824665,"share":"https://ttm.financial/m/news/2269148689?lang=&edition=fundamental","pubTime":"2022-09-22 13:31","market":"us","language":"en","title":"Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2269148689","media":"Zacks","summary":"Bluebird Bio (BLUE) shares soared 15.7% in the last trading session to close at $6.86. The move was ","content":"<html><body><p>Bluebird Bio (BLUE) shares soared 15.7% in the last trading session to close at $6.86. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.3% gain over the past four weeks.</p>\n<p>Shares surged as investors are impressed by bluebird’s recent pipeline progress. The company recently received accelerated FDA approval for its gene therapy candidate, Syskona (eli-cel) for cerebral adrenoleukodystrophy (CALD). FDA also lifted the clinical hold on the eli-cel clinical development program. Bluebird’s other gene therapy candidate Zynteglo (beti-cel) for beta-thalassemia was approved by the FDA in August.</p>\n<p>This biotechnology company is expected to post quarterly loss of $1.27 per share in its upcoming report, which represents a year-over-year change of +56.7%. Revenues are expected to be $2.15 million, down 90.5% from the year-ago quarter.</p>\n<p>Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.</p>\n<p>For Bluebird, the consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BLUE going forward to see if this recent jump can turn into more strength down the road.</p>\n<p>The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here &gt;&gt;&gt;&gt;</p>\n<p>Bluebird belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, <a href=\"https://laohu8.com/S/INSM\">Insmed</a> (INSM), closed the last trading session 1.5% lower at $23.78. Over the past month, INSM has returned -5.3%.</p>\n<p>For Insmed , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.87. This represents a change of +9.4% from what the company reported a year ago. Insmed currently has a Zacks Rank of #3 (Hold).</p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\nbluebird bio, Inc. (BLUE) : Free Stock Analysis Report\n<br/> \n<br/>\nInsmed, Inc. (INSM) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research</body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-22 13:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bluebird-blue-surges-15-7-053105544.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bluebird Bio (BLUE) shares soared 15.7% in the last trading session to close at $6.86. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bluebird-blue-surges-15-7-053105544.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/IBCgya6.haIXO4Tbb9SWfg--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/YNmIxKyqeY2cJsdQKlmFIw--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/e214749b95a51c33aa5832af03e6869b","relate_stocks":{"BLUE":"bluebird bio Inc.","BK4556":"基因编辑","BK4139":"生物科技","INSM":"Insmed","BK4578":"CAR-T"},"source_url":"https://finance.yahoo.com/news/bluebird-blue-surges-15-7-053105544.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2269148689","content_text":"Bluebird Bio (BLUE) shares soared 15.7% in the last trading session to close at $6.86. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.3% gain over the past four weeks.\nShares surged as investors are impressed by bluebird’s recent pipeline progress. The company recently received accelerated FDA approval for its gene therapy candidate, Syskona (eli-cel) for cerebral adrenoleukodystrophy (CALD). FDA also lifted the clinical hold on the eli-cel clinical development program. Bluebird’s other gene therapy candidate Zynteglo (beti-cel) for beta-thalassemia was approved by the FDA in August.\nThis biotechnology company is expected to post quarterly loss of $1.27 per share in its upcoming report, which represents a year-over-year change of +56.7%. Revenues are expected to be $2.15 million, down 90.5% from the year-ago quarter.\nEarnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.\nFor Bluebird, the consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BLUE going forward to see if this recent jump can turn into more strength down the road.\nThe stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>\nBluebird belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Insmed (INSM), closed the last trading session 1.5% lower at $23.78. Over the past month, INSM has returned -5.3%.\nFor Insmed , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.87. This represents a change of +9.4% from what the company reported a year ago. Insmed currently has a Zacks Rank of #3 (Hold).\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nbluebird bio, Inc. (BLUE) : Free Stock Analysis Report\n \n\nInsmed, Inc. (INSM) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":232,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910691126,"gmtCreate":1663610464666,"gmtModify":1676537300344,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍","listText":"Keep going 👍","text":"Keep going 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910691126","repostId":"2268990611","repostType":2,"repost":{"id":"2268990611","kind":"news","pubTimestamp":1663608896,"share":"https://ttm.financial/m/news/2268990611?lang=&edition=fundamental","pubTime":"2022-09-20 01:34","market":"hk","language":"en","title":"bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD","url":"https://stock-news.laohu8.com/highlight/detail?id=2268990611","media":"Nasdaq","summary":"bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD","content":"<div>\n<p>bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD</p>\n\n<a href=\"https://www.nasdaq.com/articles/bluebirds-blue-gene-therapy-gets-fda-nod-for-cald\">Web Link</a>\n\n</div>\n","source":"redbox_crawler","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nbluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-20 01:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/bluebirds-blue-gene-therapy-gets-fda-nod-for-cald><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD</p>\n\n<a href=\"https://www.nasdaq.com/articles/bluebirds-blue-gene-therapy-gets-fda-nod-for-cald\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4578":"CAR-T","BK4139":"生物科技","BLUE":"bluebird bio Inc.","BK4556":"基因编辑"},"source_url":"https://www.nasdaq.com/articles/bluebirds-blue-gene-therapy-gets-fda-nod-for-cald","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2268990611","content_text":"bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD","news_type":1},"isVote":1,"tweetType":1,"viewCount":163,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910118672,"gmtCreate":1663574858396,"gmtModify":1676537293634,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910118672","repostId":"2268403626","repostType":2,"repost":{"id":"2268403626","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1663387661,"share":"https://ttm.financial/m/news/2268403626?lang=&edition=fundamental","pubTime":"2022-09-17 12:07","market":"us","language":"en","title":"U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2268403626","media":"Reuters","summary":"Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the ","content":"<html><body><p>Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.</p><p>   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy <a href=\"https://laohu8.com/S/CALD\">$(CALD)$</a>, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\"</p><p> (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)</p><p>((mrinalika.roy@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-09-17 12:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.</p><p>   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy <a href=\"https://laohu8.com/S/CALD\">$(CALD)$</a>, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\"</p><p> (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)</p><p>((mrinalika.roy@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4556":"基因编辑","BLUE":"bluebird bio Inc.","BK4578":"CAR-T","BK4139":"生物科技"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2268403626","content_text":"Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy $(CALD)$, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\" (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)((mrinalika.roy@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":436,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934677665,"gmtCreate":1663250039257,"gmtModify":1676537236428,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934677665","repostId":"2267500259","repostType":2,"repost":{"id":"2267500259","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1663238700,"share":"https://ttm.financial/m/news/2267500259?lang=&edition=fundamental","pubTime":"2022-09-15 18:45","market":"us","language":"en","title":"Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2267500259","media":"T-Reuters","summary":"Aditxt Inc :Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Wa","content":"<html><body><p>Aditxt Inc <adtx.o>:Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</adtx.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-09-15 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Aditxt Inc <adtx.o>:Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</adtx.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CGEM":"Cullinan Therapeutics","APR":"Apria, Inc.","ADTX":"ADiTx Therapeutics","BK4196":"保健护理服务","BK4023":"应用软件","LABP":"Landos Biopharma, Inc.","ONTF":"ON24, Inc.","BK4082":"医疗保健设备","BK4139":"生物科技","SANA":"Sana Biotechnology, Inc.","LHDX":"Lucira Health, Inc.","BK4007":"制药"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2267500259","content_text":"Aditxt Inc :Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1},"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934984863,"gmtCreate":1663181239552,"gmtModify":1676537220433,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934984863","repostId":"1163730604","repostType":2,"repost":{"id":"1163730604","kind":"news","pubTimestamp":1662013072,"share":"https://ttm.financial/m/news/1163730604?lang=&edition=fundamental","pubTime":"2022-09-01 14:17","market":"us","language":"en","title":"Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery","url":"https://stock-news.laohu8.com/highlight/detail?id=1163730604","media":"Bloomberg","summary":"Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than sever","content":"<html><head></head><body><ul><li>Addentax’s shares soared, bringing market cap to $20 billion</li><li>Company is now valued at more than several S&amp;P 500 firms</li></ul><p>Another Chinese firm is baffling investors with massive gains on its first day of trading in the US, following on from stellar debuts for AMTD Digital Inc. and Magic Empire Global Ltd.</p><p>Addentax Group Corp.soared as much as 13,031% on Wednesday in its debut session, triggering more than 20 volatilityhalts. Its market capitalization has ballooned to $20 billion, making it bigger than about a third of S&amp;P 500 Index members.</p><p><img src=\"https://static.tigerbbs.com/ddd0e0e45fb9b77adb7a75accb44c52d\" tg-width=\"620\" tg-height=\"348\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Addentax, which lists garment manufacturing and logistics services among its key businesses, is at least the eighth firm this year from Hong Kong or China to experience similarly surprising moves following initial public offerings in the US. The Nevada-based holding company did not immediately respond to an emailed seeking comment and calls to numbers listed on its website went unanswered.</p><p>AMTD Digital and Magic Empire, both of which are financial services companies based in Hong Kong, made headlines earlier this quarter as shares mysteriously soared by thousands of percent despite opaque fundamentals, before the rallies fizzled out. AMTD Digital Inc. at one pointbecamebigger than Goldman Sachs Group Inc.</p><p>“The driving force behind the Addentax Group’s price seemingly deliberately duplicates the story of HKD and MEGL, which also experienced an unprecedented share-price frenzy recently,” said Hebe Chen, an analyst at IG Markets Ltd.</p><p>She said the commonality between them includes the fact that they all come from traditional industries and have not-so-stellar financials.</p><p>Listed originally in 2015, when it identified itself as ashell company, Addentax in December 2016 acquired a key stake in its current major operating entity called Yingxi Industrial Chain Group Co. The company was trading on an over-the-counter market for US stocks called OTCQB Marketplace prior to its listing on the Nasdaq this week.</p><p>Sponsored ContentHow Will Corporates Shape the Path to a Cleaner Future?Yokogawa</p><p>According to itsprospectus, Addentax used the same underwriter -- Network 1 Financial Securities Inc. -- as Magic Empire.</p><h2>Modest Revenues</h2><p>Like Magic Empire and AMTD Digital, Addentax has modest revenues that allow for relaxed disclosure requirements under US laws. For the year ended March, revenue dropped 49% to $12.7 million but it turned a profit, according to the prospectus.</p><p>Chen from IG Markets says it is “more than likely” that the Addentax will follow the pathway of AMTD and Magic Empire soon. The latter two have lost more than 90% from their respective peaks.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Stock’s 13,000% Surge Creates Another US IPO Mystery\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-01 14:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATXG":"盈喜集团","HKD":"尚乘数科","AMTD":"Amtd Idea","MEGL":"智富融资"},"source_url":"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163730604","content_text":"Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of trading in the US, following on from stellar debuts for AMTD Digital Inc. and Magic Empire Global Ltd.Addentax Group Corp.soared as much as 13,031% on Wednesday in its debut session, triggering more than 20 volatilityhalts. Its market capitalization has ballooned to $20 billion, making it bigger than about a third of S&P 500 Index members.Addentax, which lists garment manufacturing and logistics services among its key businesses, is at least the eighth firm this year from Hong Kong or China to experience similarly surprising moves following initial public offerings in the US. The Nevada-based holding company did not immediately respond to an emailed seeking comment and calls to numbers listed on its website went unanswered.AMTD Digital and Magic Empire, both of which are financial services companies based in Hong Kong, made headlines earlier this quarter as shares mysteriously soared by thousands of percent despite opaque fundamentals, before the rallies fizzled out. AMTD Digital Inc. at one pointbecamebigger than Goldman Sachs Group Inc.“The driving force behind the Addentax Group’s price seemingly deliberately duplicates the story of HKD and MEGL, which also experienced an unprecedented share-price frenzy recently,” said Hebe Chen, an analyst at IG Markets Ltd.She said the commonality between them includes the fact that they all come from traditional industries and have not-so-stellar financials.Listed originally in 2015, when it identified itself as ashell company, Addentax in December 2016 acquired a key stake in its current major operating entity called Yingxi Industrial Chain Group Co. The company was trading on an over-the-counter market for US stocks called OTCQB Marketplace prior to its listing on the Nasdaq this week.Sponsored ContentHow Will Corporates Shape the Path to a Cleaner Future?YokogawaAccording to itsprospectus, Addentax used the same underwriter -- Network 1 Financial Securities Inc. -- as Magic Empire.Modest RevenuesLike Magic Empire and AMTD Digital, Addentax has modest revenues that allow for relaxed disclosure requirements under US laws. For the year ended March, revenue dropped 49% to $12.7 million but it turned a profit, according to the prospectus.Chen from IG Markets says it is “more than likely” that the Addentax will follow the pathway of AMTD and Magic Empire soon. The latter two have lost more than 90% from their respective peaks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9938348295,"gmtCreate":1662565020117,"gmtModify":1676537089605,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9938348295","repostId":"2265017007","repostType":2,"repost":{"id":"2265017007","kind":"highlight","pubTimestamp":1662487350,"share":"https://ttm.financial/m/news/2265017007?lang=&edition=fundamental","pubTime":"2022-09-07 02:02","market":"us","language":"en","title":"Newly public Shuttle Pharmaceuticals shares rally 70% after plunging in prior session","url":"https://stock-news.laohu8.com/highlight/detail?id=2265017007","media":"seekingalpha","summary":"Newly public Shuttle Pharmaceuticals (NASDAQ:SHPH) stock rallied 70% midday Tuesday after tumbling 7","content":"<html><body> <p>Newly public Shuttle Pharmaceuticals (<span>NASDAQ:SHPH</span>) stock rallied 70% midday Tuesday after tumbling 72% in the prior session.</p> <p>Shares of Shuttle opened at $12.16, reaching a high of $31.19 in early afternoon. The shares recently changed hands at $25.31, up 70% from<span> Friday's close, at approximately 1:20 p.m. ET.</span></p> <p>Shuttle shares have traded widely since the company held a $10M initial public offering last Wednesday. The stock soared 373% during its first session and another 36% for its second before plunging 72% on Friday.</p> <p>Based in Maryland, Shuttle has been working on treatments to help boost the effectiveness of radiation therapies for cancer.</p> <p>For a more in-depth look at Shuttle, check out SA contributor Donovan Jones’s “Shuttle Pharmaceuticals Targets $14 Million IPO for Radiation Therapy Enhancement”.</p> <div> </div></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Newly public Shuttle Pharmaceuticals shares rally 70% after plunging in prior session</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNewly public Shuttle Pharmaceuticals shares rally 70% after plunging in prior session\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-07 02:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3880542-newly-public-shuttle-pharmaceuticals-shares-rally-after-plunging-in-prior-session><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Newly public Shuttle Pharmaceuticals (NASDAQ:SHPH) stock rallied 70% midday Tuesday after tumbling 72% in the prior session. Shares of Shuttle opened at $12.16, reaching a high of $31.19 in early ...</p>\n\n<a href=\"https://seekingalpha.com/news/3880542-newly-public-shuttle-pharmaceuticals-shares-rally-after-plunging-in-prior-session\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","SHPH":"Shuttle Pharmaceuticals Inc"},"source_url":"https://seekingalpha.com/news/3880542-newly-public-shuttle-pharmaceuticals-shares-rally-after-plunging-in-prior-session","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2265017007","content_text":"Newly public Shuttle Pharmaceuticals (NASDAQ:SHPH) stock rallied 70% midday Tuesday after tumbling 72% in the prior session. Shares of Shuttle opened at $12.16, reaching a high of $31.19 in early afternoon. The shares recently changed hands at $25.31, up 70% from Friday's close, at approximately 1:20 p.m. ET. Shuttle shares have traded widely since the company held a $10M initial public offering last Wednesday. The stock soared 373% during its first session and another 36% for its second before plunging 72% on Friday. Based in Maryland, Shuttle has been working on treatments to help boost the effectiveness of radiation therapies for cancer. For a more in-depth look at Shuttle, check out SA contributor Donovan Jones’s “Shuttle Pharmaceuticals Targets $14 Million IPO for Radiation Therapy Enhancement”.","news_type":1},"isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9931582422,"gmtCreate":1662480247167,"gmtModify":1676537070284,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9931582422","repostId":"2264753166","repostType":2,"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9939595948,"gmtCreate":1662129249985,"gmtModify":1676537004260,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939595948","repostId":"2264820774","repostType":2,"isVote":1,"tweetType":1,"viewCount":31,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9939226859,"gmtCreate":1662120837471,"gmtModify":1676537002283,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939226859","repostId":"2264741732","repostType":2,"isVote":1,"tweetType":1,"viewCount":47,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9930623565,"gmtCreate":1661953513558,"gmtModify":1676536610788,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪💪","listText":"💪💪","text":"💪💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930623565","repostId":"2263407776","repostType":2,"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9995742906,"gmtCreate":1661524131452,"gmtModify":1676536534967,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going&nbsp;","listText":"Keep going&nbsp;","text":"Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9995742906","repostId":"2262924028","repostType":2,"repost":{"id":"2262924028","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1661520660,"share":"https://ttm.financial/m/news/2262924028?lang=&edition=fundamental","pubTime":"2022-08-26 21:31","market":"us","language":"en","title":"Micro Focus Takeover Likely to Go Through Given Industry Trends -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2262924028","media":"Dow Jones","summary":"1331 GMT - The deal for Open Text to buy Micro Focus International for GBP1.8 billion is most likely","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1331 GMT - The deal for Open Text to buy Micro Focus International for GBP1.8 billion is most likely go through given the industry trend toward consolidation and going private, the bid premium and support from the the U.K. software group's board, Citi analysts say in a research note. While a rival bid can't be ruled out, it seems unlikely considering that most peers have already been taken private, they say. If such a bid were to come, they say it would probably come from a financial sponsor or private equity. Citi has a neutral/high-risk rating on the stock with a target price of 530 pence. Shares trade up 95% at 521.20 pence. (kyle.morris@dowjones.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 26, 2022 09:31 ET (13:31 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Micro Focus Takeover Likely to Go Through Given Industry Trends -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicro Focus Takeover Likely to Go Through Given Industry Trends -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-08-26 21:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1331 GMT - The deal for Open Text to buy Micro Focus International for GBP1.8 billion is most likely go through given the industry trend toward consolidation and going private, the bid premium and support from the the U.K. software group's board, Citi analysts say in a research note. While a rival bid can't be ruled out, it seems unlikely considering that most peers have already been taken private, they say. If such a bid were to come, they say it would probably come from a financial sponsor or private equity. Citi has a neutral/high-risk rating on the stock with a target price of 530 pence. Shares trade up 95% at 521.20 pence. (kyle.morris@dowjones.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 26, 2022 09:31 ET (13:31 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4023":"应用软件","MFGP":"Micro Focus Intl PLC"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2262924028","content_text":"1331 GMT - The deal for Open Text to buy Micro Focus International for GBP1.8 billion is most likely go through given the industry trend toward consolidation and going private, the bid premium and support from the the U.K. software group's board, Citi analysts say in a research note. While a rival bid can't be ruled out, it seems unlikely considering that most peers have already been taken private, they say. If such a bid were to come, they say it would probably come from a financial sponsor or private equity. Citi has a neutral/high-risk rating on the stock with a target price of 530 pence. Shares trade up 95% at 521.20 pence. (kyle.morris@dowjones.com) \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 26, 2022 09:31 ET (13:31 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9995746673,"gmtCreate":1661524004094,"gmtModify":1676536534951,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going&nbsp;","listText":"Keep going&nbsp;","text":"Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9995746673","repostId":"2262927014","repostType":2,"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9992442729,"gmtCreate":1661366996163,"gmtModify":1676536503565,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep it going&nbsp;","listText":"Keep it going&nbsp;","text":"Keep it going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9992442729","repostId":"2262567869","repostType":2,"repost":{"id":"2262567869","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1661365560,"share":"https://ttm.financial/m/news/2262567869?lang=&edition=fundamental","pubTime":"2022-08-25 02:26","market":"us","language":"en","title":"Trending: Bed Bath & Beyond Finds a Lender, Sources Say","url":"https://stock-news.laohu8.com/highlight/detail?id=2262567869","media":"Dow Jones","summary":"14:26 ET -- Bed Bath & Beyond Inc. is one of the most talked-about companies in the U.S. across all ","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  14:26 ET -- Bed Bath &amp; Beyond Inc. is one of the most talked-about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The home goods retailer disclosed it has a lender for a loan deal to help provide liquidity, according to people familiar with the matter. The Wall Street Journal previously reported the company was seeking about $375 million to help cash levels and pay down debt. Terms of the possible final deal weren't disclosed. Dow Jones &amp; Co. owns Factiva.(jennifer.tershak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 24, 2022 14:26 ET (18:26 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trending: Bed Bath & Beyond Finds a Lender, Sources Say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrending: Bed Bath & Beyond Finds a Lender, Sources Say\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-08-25 02:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  14:26 ET -- Bed Bath &amp; Beyond Inc. is one of the most talked-about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The home goods retailer disclosed it has a lender for a loan deal to help provide liquidity, according to people familiar with the matter. The Wall Street Journal previously reported the company was seeking about $375 million to help cash levels and pay down debt. Terms of the possible final deal weren't disclosed. Dow Jones &amp; Co. owns Factiva.(jennifer.tershak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 24, 2022 14:26 ET (18:26 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4547":"WSB热门概念","BK4178":"家庭装饰零售","BBBY":"3B家居"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2262567869","content_text":"14:26 ET -- Bed Bath & Beyond Inc. is one of the most talked-about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The home goods retailer disclosed it has a lender for a loan deal to help provide liquidity, according to people familiar with the matter. The Wall Street Journal previously reported the company was seeking about $375 million to help cash levels and pay down debt. Terms of the possible final deal weren't disclosed. Dow Jones & Co. owns Factiva.(jennifer.tershak@wsj.com) \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 24, 2022 14:26 ET (18:26 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":36,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9992493616,"gmtCreate":1661350470538,"gmtModify":1676536501348,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep it going&nbsp;","listText":"Keep it going&nbsp;","text":"Keep it going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9992493616","repostId":"1143885737","repostType":2,"repost":{"id":"1143885737","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1661328234,"share":"https://ttm.financial/m/news/1143885737?lang=&edition=fundamental","pubTime":"2022-08-24 16:03","market":"us","language":"en","title":"Starbox Shares Jumped 22% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1143885737","media":"Tiger Newspress","summary":"Starbox shares jumped 22% in premarket trading. The shares soared nearly 290% on the first day of li","content":"<html><head></head><body><p>Starbox shares jumped 22% in premarket trading. The shares soared nearly 290% on the first day of listing.</p><p><img src=\"https://static.tigerbbs.com/425e5563e091dc36b24955774a3cccb4\" tg-width=\"1407\" tg-height=\"606\" referrerpolicy=\"no-referrer\"/></p><p>Malaysia-based fintech <a href=\"https://laohu8.com/S/STBX\">Starbox</a> Group (NASDAQ:STBX) saw its shares once soared as high as 1,055% on Tuesday in the wake of its $20M initial public offering.</p><p>Shares of Starbox opened at $27, rocketing to a high of $46.21 before dropping to $15.40.</p><p>Starbox offered 5M shares priced at $4 per share, raising around $20M. The company provides cash rebate, digital advertising and payment solution services to micro, small and medium-sized businesses.</p><p>Shares were priced at the lower end of its previously proposed range of $4 to $5 per share.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Starbox Shares Jumped 22% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStarbox Shares Jumped 22% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-08-24 16:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Starbox shares jumped 22% in premarket trading. The shares soared nearly 290% on the first day of listing.</p><p><img src=\"https://static.tigerbbs.com/425e5563e091dc36b24955774a3cccb4\" tg-width=\"1407\" tg-height=\"606\" referrerpolicy=\"no-referrer\"/></p><p>Malaysia-based fintech <a href=\"https://laohu8.com/S/STBX\">Starbox</a> Group (NASDAQ:STBX) saw its shares once soared as high as 1,055% on Tuesday in the wake of its $20M initial public offering.</p><p>Shares of Starbox opened at $27, rocketing to a high of $46.21 before dropping to $15.40.</p><p>Starbox offered 5M shares priced at $4 per share, raising around $20M. The company provides cash rebate, digital advertising and payment solution services to micro, small and medium-sized businesses.</p><p>Shares were priced at the lower end of its previously proposed range of $4 to $5 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STBX":"Starbox"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143885737","content_text":"Starbox shares jumped 22% in premarket trading. The shares soared nearly 290% on the first day of listing.Malaysia-based fintech Starbox Group (NASDAQ:STBX) saw its shares once soared as high as 1,055% on Tuesday in the wake of its $20M initial public offering.Shares of Starbox opened at $27, rocketing to a high of $46.21 before dropping to $15.40.Starbox offered 5M shares priced at $4 per share, raising around $20M. The company provides cash rebate, digital advertising and payment solution services to micro, small and medium-sized businesses.Shares were priced at the lower end of its previously proposed range of $4 to $5 per share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":49,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9902594590,"gmtCreate":1659719695912,"gmtModify":1704335957767,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍💪","listText":"Keep going 👍💪","text":"Keep going 👍💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9902594590","repostId":"2257197900","repostType":2,"repost":{"id":"2257197900","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1659713820,"share":"https://ttm.financial/m/news/2257197900?lang=&edition=fundamental","pubTime":"2022-08-05 23:37","market":"us","language":"en","title":"Applied DNA stock surges again, for 4-day gain of more than 870%","url":"https://stock-news.laohu8.com/highlight/detail?id=2257197900","media":"Dow Jones","summary":"MW Applied DNA stock surges again, for 4-day gain of more than 870%\n\n\n  Shares of Applied DNA Scienc","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Applied DNA stock surges again, for 4-day gain of more than 870%\n</p>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/APDNW\">Applied DNA Sciences Inc</a>. <a href=\"https://laohu8.com/S/APDN\">$(APDN)$</a> jumped another 15.2% in morning trading Friday, to snap back from an earlier intraday loss of as much as 8.7%. The biotechnology company's stock has now skyrocketed 873.5% amid a four-day win streak, which kicked off with a 311.2% gain on Tuesday after the company said it initiated validation of a monkeypox virus test. Trading volume as of Friday morning was 23.1 million shares, after averaging 109.5 million shares a day for the past three days; that has increased the full-day average for the past 90 days to 3.8 million shares. The stock has now run up 64.4% year to date, while the <a href=\"https://laohu8.com/S/EMDI\">iShares</a> Biotechnology ETF <a href=\"https://laohu8.com/S/IBB\">$(IBB)$</a> has dropped 26.2% and the S&amp;P 500  has lost 13.6%. \n</p>\n<p>\n  -Tomi Kilgore \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 05, 2022 11:37 ET (15:37 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied DNA stock surges again, for 4-day gain of more than 870%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied DNA stock surges again, for 4-day gain of more than 870%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-08-05 23:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Applied DNA stock surges again, for 4-day gain of more than 870%\n</p>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/APDNW\">Applied DNA Sciences Inc</a>. <a href=\"https://laohu8.com/S/APDN\">$(APDN)$</a> jumped another 15.2% in morning trading Friday, to snap back from an earlier intraday loss of as much as 8.7%. The biotechnology company's stock has now skyrocketed 873.5% amid a four-day win streak, which kicked off with a 311.2% gain on Tuesday after the company said it initiated validation of a monkeypox virus test. Trading volume as of Friday morning was 23.1 million shares, after averaging 109.5 million shares a day for the past three days; that has increased the full-day average for the past 90 days to 3.8 million shares. The stock has now run up 64.4% year to date, while the <a href=\"https://laohu8.com/S/EMDI\">iShares</a> Biotechnology ETF <a href=\"https://laohu8.com/S/IBB\">$(IBB)$</a> has dropped 26.2% and the S&amp;P 500  has lost 13.6%. \n</p>\n<p>\n  -Tomi Kilgore \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 05, 2022 11:37 ET (15:37 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4109":"特种化学制品","APDN":"Applied DNA Sciences Inc","DNA":"Ginkgo Bioworks Holdings Inc.","BK4139":"生物科技","IBB":"生物科技指数ETF-iShares Nasdaq"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2257197900","content_text":"MW Applied DNA stock surges again, for 4-day gain of more than 870%\n\n\n  Shares of Applied DNA Sciences Inc. $(APDN)$ jumped another 15.2% in morning trading Friday, to snap back from an earlier intraday loss of as much as 8.7%. The biotechnology company's stock has now skyrocketed 873.5% amid a four-day win streak, which kicked off with a 311.2% gain on Tuesday after the company said it initiated validation of a monkeypox virus test. Trading volume as of Friday morning was 23.1 million shares, after averaging 109.5 million shares a day for the past three days; that has increased the full-day average for the past 90 days to 3.8 million shares. The stock has now run up 64.4% year to date, while the iShares Biotechnology ETF $(IBB)$ has dropped 26.2% and the S&P 500  has lost 13.6%. \n\n\n  -Tomi Kilgore \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 05, 2022 11:37 ET (15:37 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9062752274,"gmtCreate":1652110674899,"gmtModify":1676535031788,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ZYME\">$Zymeworks Inc.(ZYME)$</a>&nbsp;do people realise that the projected&nbsp;share price from analysts are in the range of $15 to 45?! 😅 However, Zymeworks is falling to its all time low 🤯 how?&nbsp;","listText":"<a href=\"https://ttm.financial/S/ZYME\">$Zymeworks Inc.(ZYME)$</a>&nbsp;do people realise that the projected&nbsp;share price from analysts are in the range of $15 to 45?! 😅 However, Zymeworks is falling to its all time low 🤯 how?&nbsp;","text":"$Zymeworks Inc.(ZYME)$ do people realise that the projected share price from analysts are in the range of $15 to 45?! 😅 However, Zymeworks is falling to its all time low 🤯 how?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/9062752274","isVote":1,"tweetType":1,"viewCount":740,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000701","authorId":"9000000000000701","name":"AthenaVeblen","avatar":"https://static.tigerbbs.com/fb48733f77d50133639e148b840f87ae","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000701","authorIdStr":"9000000000000701"},"content":"Now the change of stock price is difficult to explain in theory.","text":"Now the change of stock price is difficult to explain in theory.","html":"Now the change of stock price is difficult to explain in theory."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081339814,"gmtCreate":1650193945166,"gmtModify":1676534666571,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Absolutely gambling and draws in the opportunists before dropping us all in it. Not exactly a skill but just how long you want to tag along&nbsp;","listText":"Absolutely gambling and draws in the opportunists before dropping us all in it. Not exactly a skill but just how long you want to tag along&nbsp;","text":"Absolutely gambling and draws in the opportunists before dropping us all in it. Not exactly a skill but just how long you want to tag along","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081339814","repostId":"2227673974","repostType":2,"repost":{"id":"2227673974","kind":"news","pubTimestamp":1649954820,"share":"https://ttm.financial/m/news/2227673974?lang=&edition=fundamental","pubTime":"2022-04-15 00:47","market":"us","language":"en","title":"Newly public Genius Group stock drops 50% following monster IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2227673974","media":"seekingalpha","summary":"Newly public edtech Genius Group (GNS) stock dropped more than 50% Thursday just two days after scor","content":"<html><body><p>Newly public edtech Genius Group (GNS) stock dropped more than 50% Thursday just two days after scoring spectacular gains following<span> its $22.6M initial public offering.</span></p> <p>Shares of the Singapore-based educational services company opened at $19.57, hitting a high of $20.94 before sliding to a low of $9.30. The stock recently changed hands at $9.00, down 53%, at approximately 11:20 a.m. ET.</p> <p>Genius shares soared more than 400% on Tuesday following their market debut. The company offered 3.3M shares priced at $6 per share, with underwriters granted an option to buy up to 491K additional shares at the public price. Shares opened at $15.11 and closed at $30.50.</p> <p>The stock lost ground the following day, however, closing at $19.43, down 36% from the previous session.</p> <p>For a more in-depth look at Genius Group, check out SA contributor Donovan Jones’s “IPO Update: Genius Group Seeks $40 Million US IPO”.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Newly public Genius Group stock drops 50% following monster IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNewly public Genius Group stock drops 50% following monster IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-15 00:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3823508-newly-public-genius-group-stock-drops-50-percent-following-monster-ipo><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Newly public edtech Genius Group (GNS) stock dropped more than 50% Thursday just two days after scoring spectacular gains following its $22.6M initial public offering. Shares of the Singapore-based ...</p>\n\n<a href=\"https://seekingalpha.com/news/3823508-newly-public-genius-group-stock-drops-50-percent-following-monster-ipo\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GNS":"Genius Group Limited"},"source_url":"https://seekingalpha.com/news/3823508-newly-public-genius-group-stock-drops-50-percent-following-monster-ipo","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2227673974","content_text":"Newly public edtech Genius Group (GNS) stock dropped more than 50% Thursday just two days after scoring spectacular gains following its $22.6M initial public offering. Shares of the Singapore-based educational services company opened at $19.57, hitting a high of $20.94 before sliding to a low of $9.30. The stock recently changed hands at $9.00, down 53%, at approximately 11:20 a.m. ET. Genius shares soared more than 400% on Tuesday following their market debut. The company offered 3.3M shares priced at $6 per share, with underwriters granted an option to buy up to 491K additional shares at the public price. Shares opened at $15.11 and closed at $30.50. The stock lost ground the following day, however, closing at $19.43, down 36% from the previous session. For a more in-depth look at Genius Group, check out SA contributor Donovan Jones’s “IPO Update: Genius Group Seeks $40 Million US IPO”.","news_type":1},"isVote":1,"tweetType":1,"viewCount":31,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9067643730,"gmtCreate":1652458509720,"gmtModify":1676535105022,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ASNS\">$Actelis Networks Inc(ASNS)$</a>&nbsp;does this look like $4 a share?! 😅","listText":"<a href=\"https://ttm.financial/S/ASNS\">$Actelis Networks Inc(ASNS)$</a>&nbsp;does this look like $4 a share?! 😅","text":"$Actelis Networks Inc(ASNS)$ does this look like $4 a share?! 😅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9067643730","isVote":1,"tweetType":1,"viewCount":463,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934984863,"gmtCreate":1663181239552,"gmtModify":1676537220433,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934984863","repostId":"1163730604","repostType":2,"repost":{"id":"1163730604","kind":"news","pubTimestamp":1662013072,"share":"https://ttm.financial/m/news/1163730604?lang=&edition=fundamental","pubTime":"2022-09-01 14:17","market":"us","language":"en","title":"Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery","url":"https://stock-news.laohu8.com/highlight/detail?id=1163730604","media":"Bloomberg","summary":"Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than sever","content":"<html><head></head><body><ul><li>Addentax’s shares soared, bringing market cap to $20 billion</li><li>Company is now valued at more than several S&amp;P 500 firms</li></ul><p>Another Chinese firm is baffling investors with massive gains on its first day of trading in the US, following on from stellar debuts for AMTD Digital Inc. and Magic Empire Global Ltd.</p><p>Addentax Group Corp.soared as much as 13,031% on Wednesday in its debut session, triggering more than 20 volatilityhalts. Its market capitalization has ballooned to $20 billion, making it bigger than about a third of S&amp;P 500 Index members.</p><p><img src=\"https://static.tigerbbs.com/ddd0e0e45fb9b77adb7a75accb44c52d\" tg-width=\"620\" tg-height=\"348\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Addentax, which lists garment manufacturing and logistics services among its key businesses, is at least the eighth firm this year from Hong Kong or China to experience similarly surprising moves following initial public offerings in the US. The Nevada-based holding company did not immediately respond to an emailed seeking comment and calls to numbers listed on its website went unanswered.</p><p>AMTD Digital and Magic Empire, both of which are financial services companies based in Hong Kong, made headlines earlier this quarter as shares mysteriously soared by thousands of percent despite opaque fundamentals, before the rallies fizzled out. AMTD Digital Inc. at one pointbecamebigger than Goldman Sachs Group Inc.</p><p>“The driving force behind the Addentax Group’s price seemingly deliberately duplicates the story of HKD and MEGL, which also experienced an unprecedented share-price frenzy recently,” said Hebe Chen, an analyst at IG Markets Ltd.</p><p>She said the commonality between them includes the fact that they all come from traditional industries and have not-so-stellar financials.</p><p>Listed originally in 2015, when it identified itself as ashell company, Addentax in December 2016 acquired a key stake in its current major operating entity called Yingxi Industrial Chain Group Co. The company was trading on an over-the-counter market for US stocks called OTCQB Marketplace prior to its listing on the Nasdaq this week.</p><p>Sponsored ContentHow Will Corporates Shape the Path to a Cleaner Future?Yokogawa</p><p>According to itsprospectus, Addentax used the same underwriter -- Network 1 Financial Securities Inc. -- as Magic Empire.</p><h2>Modest Revenues</h2><p>Like Magic Empire and AMTD Digital, Addentax has modest revenues that allow for relaxed disclosure requirements under US laws. For the year ended March, revenue dropped 49% to $12.7 million but it turned a profit, according to the prospectus.</p><p>Chen from IG Markets says it is “more than likely” that the Addentax will follow the pathway of AMTD and Magic Empire soon. The latter two have lost more than 90% from their respective peaks.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Stock’s 13,000% Surge Creates Another US IPO Mystery\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-01 14:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATXG":"盈喜集团","HKD":"尚乘数科","AMTD":"Amtd Idea","MEGL":"智富融资"},"source_url":"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163730604","content_text":"Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of trading in the US, following on from stellar debuts for AMTD Digital Inc. and Magic Empire Global Ltd.Addentax Group Corp.soared as much as 13,031% on Wednesday in its debut session, triggering more than 20 volatilityhalts. Its market capitalization has ballooned to $20 billion, making it bigger than about a third of S&P 500 Index members.Addentax, which lists garment manufacturing and logistics services among its key businesses, is at least the eighth firm this year from Hong Kong or China to experience similarly surprising moves following initial public offerings in the US. The Nevada-based holding company did not immediately respond to an emailed seeking comment and calls to numbers listed on its website went unanswered.AMTD Digital and Magic Empire, both of which are financial services companies based in Hong Kong, made headlines earlier this quarter as shares mysteriously soared by thousands of percent despite opaque fundamentals, before the rallies fizzled out. AMTD Digital Inc. at one pointbecamebigger than Goldman Sachs Group Inc.“The driving force behind the Addentax Group’s price seemingly deliberately duplicates the story of HKD and MEGL, which also experienced an unprecedented share-price frenzy recently,” said Hebe Chen, an analyst at IG Markets Ltd.She said the commonality between them includes the fact that they all come from traditional industries and have not-so-stellar financials.Listed originally in 2015, when it identified itself as ashell company, Addentax in December 2016 acquired a key stake in its current major operating entity called Yingxi Industrial Chain Group Co. The company was trading on an over-the-counter market for US stocks called OTCQB Marketplace prior to its listing on the Nasdaq this week.Sponsored ContentHow Will Corporates Shape the Path to a Cleaner Future?YokogawaAccording to itsprospectus, Addentax used the same underwriter -- Network 1 Financial Securities Inc. -- as Magic Empire.Modest RevenuesLike Magic Empire and AMTD Digital, Addentax has modest revenues that allow for relaxed disclosure requirements under US laws. For the year ended March, revenue dropped 49% to $12.7 million but it turned a profit, according to the prospectus.Chen from IG Markets says it is “more than likely” that the Addentax will follow the pathway of AMTD and Magic Empire soon. The latter two have lost more than 90% from their respective peaks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9943069212,"gmtCreate":1678970053837,"gmtModify":1678970057873,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep the faith&nbsp;","listText":"Keep the faith&nbsp;","text":"Keep the faith","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943069212","repostId":"2319635989","repostType":2,"isVote":1,"tweetType":1,"viewCount":352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9926346415,"gmtCreate":1671475343437,"gmtModify":1676538542689,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926346415","repostId":"2292878348","repostType":2,"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921919543,"gmtCreate":1670952901482,"gmtModify":1676538466261,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919543","repostId":"2291739039","repostType":2,"isVote":1,"tweetType":1,"viewCount":330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921919295,"gmtCreate":1670952878417,"gmtModify":1676538466259,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919295","repostId":"2291146287","repostType":2,"isVote":1,"tweetType":1,"viewCount":307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9915528738,"gmtCreate":1665076334724,"gmtModify":1676537553407,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9915528738","repostId":"2273255383","repostType":2,"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9919401161,"gmtCreate":1663833732953,"gmtModify":1676537346296,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍","listText":"Keep going 👍","text":"Keep going 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9919401161","repostId":"2269148689","repostType":2,"repost":{"id":"2269148689","kind":"highlight","pubTimestamp":1663824665,"share":"https://ttm.financial/m/news/2269148689?lang=&edition=fundamental","pubTime":"2022-09-22 13:31","market":"us","language":"en","title":"Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2269148689","media":"Zacks","summary":"Bluebird Bio (BLUE) shares soared 15.7% in the last trading session to close at $6.86. The move was ","content":"<html><body><p>Bluebird Bio (BLUE) shares soared 15.7% in the last trading session to close at $6.86. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.3% gain over the past four weeks.</p>\n<p>Shares surged as investors are impressed by bluebird’s recent pipeline progress. The company recently received accelerated FDA approval for its gene therapy candidate, Syskona (eli-cel) for cerebral adrenoleukodystrophy (CALD). FDA also lifted the clinical hold on the eli-cel clinical development program. Bluebird’s other gene therapy candidate Zynteglo (beti-cel) for beta-thalassemia was approved by the FDA in August.</p>\n<p>This biotechnology company is expected to post quarterly loss of $1.27 per share in its upcoming report, which represents a year-over-year change of +56.7%. Revenues are expected to be $2.15 million, down 90.5% from the year-ago quarter.</p>\n<p>Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.</p>\n<p>For Bluebird, the consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BLUE going forward to see if this recent jump can turn into more strength down the road.</p>\n<p>The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here &gt;&gt;&gt;&gt;</p>\n<p>Bluebird belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, <a href=\"https://laohu8.com/S/INSM\">Insmed</a> (INSM), closed the last trading session 1.5% lower at $23.78. Over the past month, INSM has returned -5.3%.</p>\n<p>For Insmed , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.87. This represents a change of +9.4% from what the company reported a year ago. Insmed currently has a Zacks Rank of #3 (Hold).</p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\nbluebird bio, Inc. (BLUE) : Free Stock Analysis Report\n<br/> \n<br/>\nInsmed, Inc. (INSM) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research</body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-22 13:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bluebird-blue-surges-15-7-053105544.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bluebird Bio (BLUE) shares soared 15.7% in the last trading session to close at $6.86. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bluebird-blue-surges-15-7-053105544.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/IBCgya6.haIXO4Tbb9SWfg--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/YNmIxKyqeY2cJsdQKlmFIw--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/e214749b95a51c33aa5832af03e6869b","relate_stocks":{"BLUE":"bluebird bio Inc.","BK4556":"基因编辑","BK4139":"生物科技","INSM":"Insmed","BK4578":"CAR-T"},"source_url":"https://finance.yahoo.com/news/bluebird-blue-surges-15-7-053105544.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2269148689","content_text":"Bluebird Bio (BLUE) shares soared 15.7% in the last trading session to close at $6.86. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.3% gain over the past four weeks.\nShares surged as investors are impressed by bluebird’s recent pipeline progress. The company recently received accelerated FDA approval for its gene therapy candidate, Syskona (eli-cel) for cerebral adrenoleukodystrophy (CALD). FDA also lifted the clinical hold on the eli-cel clinical development program. Bluebird’s other gene therapy candidate Zynteglo (beti-cel) for beta-thalassemia was approved by the FDA in August.\nThis biotechnology company is expected to post quarterly loss of $1.27 per share in its upcoming report, which represents a year-over-year change of +56.7%. Revenues are expected to be $2.15 million, down 90.5% from the year-ago quarter.\nEarnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.\nFor Bluebird, the consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BLUE going forward to see if this recent jump can turn into more strength down the road.\nThe stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>\nBluebird belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Insmed (INSM), closed the last trading session 1.5% lower at $23.78. Over the past month, INSM has returned -5.3%.\nFor Insmed , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.87. This represents a change of +9.4% from what the company reported a year ago. Insmed currently has a Zacks Rank of #3 (Hold).\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nbluebird bio, Inc. (BLUE) : Free Stock Analysis Report\n \n\nInsmed, Inc. (INSM) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":232,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910691126,"gmtCreate":1663610464666,"gmtModify":1676537300344,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍","listText":"Keep going 👍","text":"Keep going 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910691126","repostId":"2268990611","repostType":2,"isVote":1,"tweetType":1,"viewCount":163,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910118672,"gmtCreate":1663574858396,"gmtModify":1676537293634,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910118672","repostId":"2268403626","repostType":2,"isVote":1,"tweetType":1,"viewCount":436,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934677665,"gmtCreate":1663250039257,"gmtModify":1676537236428,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934677665","repostId":"2267500259","repostType":2,"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9938348295,"gmtCreate":1662565020117,"gmtModify":1676537089605,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9938348295","repostId":"2265017007","repostType":2,"isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9931582422,"gmtCreate":1662480247167,"gmtModify":1676537070284,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9931582422","repostId":"2264753166","repostType":2,"repost":{"id":"2264753166","kind":"news","pubTimestamp":1662183294,"share":"https://ttm.financial/m/news/2264753166?lang=&edition=fundamental","pubTime":"2022-09-03 13:34","market":"us","language":"en","title":"Hollysys Stock: Possible Take-Private Deal? (NASDAQ:HOLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2264753166","media":"Seeking Alpha","summary":"Hollysys Stock: Possible Take-Private Deal? (NASDAQ:HOLI)","content":"<div>\n<p>Hollysys Stock: Possible Take-Private Deal? (NASDAQ:HOLI)</p>\n\n<a href=\"https://seekingalpha.com/article/4538779-hollysys-stock-possible-take-private-deal-speculative-buy\">Web Link</a>\n\n</div>\n","source":"redbox_crawler","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hollysys Stock: Possible Take-Private Deal? (NASDAQ:HOLI)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHollysys Stock: Possible Take-Private Deal? (NASDAQ:HOLI)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-03 13:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4538779-hollysys-stock-possible-take-private-deal-speculative-buy><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hollysys Stock: Possible Take-Private Deal? (NASDAQ:HOLI)</p>\n\n<a href=\"https://seekingalpha.com/article/4538779-hollysys-stock-possible-take-private-deal-speculative-buy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4580":"工业 4.0","BK4157":"电子设备和仪器","HOLI":"和利时自动化"},"source_url":"https://seekingalpha.com/article/4538779-hollysys-stock-possible-take-private-deal-speculative-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264753166","content_text":"Hollysys Stock: Possible Take-Private Deal? (NASDAQ:HOLI)","news_type":1},"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9939595948,"gmtCreate":1662129249985,"gmtModify":1676537004260,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939595948","repostId":"2264820774","repostType":2,"isVote":1,"tweetType":1,"viewCount":31,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9939226859,"gmtCreate":1662120837471,"gmtModify":1676537002283,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939226859","repostId":"2264741732","repostType":2,"repost":{"id":"2264741732","kind":"highlight","pubTimestamp":1662109059,"share":"https://ttm.financial/m/news/2264741732?lang=&edition=fundamental","pubTime":"2022-09-02 16:57","market":"us","language":"en","title":"Exclusive-Hollysys management to lead take-private deal at $1.8 billion valuation -sources","url":"https://stock-news.laohu8.com/highlight/detail?id=2264741732","media":"Reuters","summary":"By Julie Zhu \n HONG KONG (Reuters) - A consortium led by China's Hollysys Automation Technologies ma","content":"<html><body><p>By Julie Zhu </p>\n<p> HONG KONG (Reuters) - A consortium led by China's Hollysys Automation Technologies management plans to take the U.S.-listed automation and control system maker private in a deal that would value the firm at $1.8 billion, people with knowledge of the matter said. </p>\n<p> The management team, led by founder and Chief Executive Officer Wang Changli, has won endorsement for the deal from the municipal government of Beijing, where the company is based, the people said. </p>\n<p> The team, acting under the local government's guidance, has joined hands with a Beijing-based state firm for the potential deal, they added. </p>\n<p> Neither Hollysys nor Wang responded to Reuters requests for comment. The Beijing municipal government also did not respond. </p>\n<p> The planned take-private deal reflects the consortium's view that Hollysys, which was listed in New York in 2008, was undervalued in the U.S. market, the people said. </p>\n<p> Founded in 1993, the company trades at 13 times trailing earnings on the Nasdaq, while its Shanghai-listed peer Zhejiang Supcon Technology has a comparable P/E multiple of 54, according to Refinitiv data. </p>\n<p> The consortium aims to bring a number of financial investors into the take-private deal, including U.S. private equity firm Warburg Pincus and Chinese venture capital firm Legend Capital, the people said. </p>\n<p> The consortium has also held talks with banks to finance the deal and is about to secure loans worth at least $1 billion from Chinese lenders, led by ICBC (Asia), they added. </p>\n<p> State-owned lender ICBC (Asia) did not respond to a request for comment. Warburg Pincus and Legend Capital had no comment on the matter when contacted by Reuters. </p>\n<p> The people declined to be identified because the information was not public. </p>\n<p> The consortium plans to offer about $29 per share to take Hollysys private, the sources said, representing a premium of 81% to the firm's average share price over the past three months of $16. </p>\n<p> (Reporting by Julie Zhu; Editing by Sumeet Chatterjee and Edmund Klamann) </p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exclusive-Hollysys management to lead take-private deal at $1.8 billion valuation -sources</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExclusive-Hollysys management to lead take-private deal at $1.8 billion valuation -sources\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/exclusive-hollysys-management-lead-private-085739314.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Julie Zhu \n HONG KONG (Reuters) - A consortium led by China's Hollysys Automation Technologies management plans to take the U.S.-listed automation and control system maker private in a deal that ...</p>\n\n<a href=\"https://finance.yahoo.com/news/exclusive-hollysys-management-lead-private-085739314.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/1D7uAsZ41ozQ2oFHChKTTA--~B/aD01MDM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/MzCGDYAWgyLibDQDhKXYsQ--~B/aD01MDM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/3b3a18c651bb93e1ba3ab89a0bf3f906","relate_stocks":{"BK4157":"电子设备和仪器","HOLI":"和利时自动化","BK4580":"工业 4.0"},"source_url":"https://finance.yahoo.com/news/exclusive-hollysys-management-lead-private-085739314.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2264741732","content_text":"By Julie Zhu \n HONG KONG (Reuters) - A consortium led by China's Hollysys Automation Technologies management plans to take the U.S.-listed automation and control system maker private in a deal that would value the firm at $1.8 billion, people with knowledge of the matter said. \n The management team, led by founder and Chief Executive Officer Wang Changli, has won endorsement for the deal from the municipal government of Beijing, where the company is based, the people said. \n The team, acting under the local government's guidance, has joined hands with a Beijing-based state firm for the potential deal, they added. \n Neither Hollysys nor Wang responded to Reuters requests for comment. The Beijing municipal government also did not respond. \n The planned take-private deal reflects the consortium's view that Hollysys, which was listed in New York in 2008, was undervalued in the U.S. market, the people said. \n Founded in 1993, the company trades at 13 times trailing earnings on the Nasdaq, while its Shanghai-listed peer Zhejiang Supcon Technology has a comparable P/E multiple of 54, according to Refinitiv data. \n The consortium aims to bring a number of financial investors into the take-private deal, including U.S. private equity firm Warburg Pincus and Chinese venture capital firm Legend Capital, the people said. \n The consortium has also held talks with banks to finance the deal and is about to secure loans worth at least $1 billion from Chinese lenders, led by ICBC (Asia), they added. \n State-owned lender ICBC (Asia) did not respond to a request for comment. Warburg Pincus and Legend Capital had no comment on the matter when contacted by Reuters. \n The people declined to be identified because the information was not public. \n The consortium plans to offer about $29 per share to take Hollysys private, the sources said, representing a premium of 81% to the firm's average share price over the past three months of $16. \n (Reporting by Julie Zhu; Editing by Sumeet Chatterjee and Edmund Klamann)","news_type":1},"isVote":1,"tweetType":1,"viewCount":47,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9930623565,"gmtCreate":1661953513558,"gmtModify":1676536610788,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪💪","listText":"💪💪","text":"💪💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930623565","repostId":"2263407776","repostType":2,"repost":{"id":"2263407776","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1661953108,"share":"https://ttm.financial/m/news/2263407776?lang=&edition=fundamental","pubTime":"2022-08-31 21:38","market":"us","language":"en","title":"BRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2263407776","media":"Reuters","summary":"Aug 31 (Reuters) - Bed Bath & Beyond Inc   :   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FIN","content":"<html><body><p>Aug 31 (Reuters) - Bed Bath &amp; Beyond Inc   :</p><p>   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FINANCIAL POSITIONING, DRIVE GROWTH AND BETTER SERVE CUSTOMERS</p><p>   * SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * ANNOUNCED IT HAS SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * HAS BEGUN IMPLEMENTING SIGNIFICANT, ADDITIONAL SG&amp;A REDUCTIONS TO RIGHT-SIZE ITS COST STRUCTURE</p><p>   * BED BATH &amp; BEYOND - SECURED FINANCING COMMITMENTS INCLUDING ITS NEWLY EXPANDED $1.13 BILLION ABL FACILITY AND A NEW $375 MILLION FILO FACILITY</p><p>   * COST OPTIMIZATION PLANS INCLUDE A REDUCTION IN FORCE, INCLUDING APPROXIMATELY 20% ACROSS CORPORATE AND SUPPLY CHAIN</p><p>   * IDENTIFIED AND COMMENCED CLOSURE OF APPROXIMATELY 150 LOWER-PRODUCING BED BATH &amp; BEYOND BANNER STORES</p><p>   * EXPECTS ACTIONS ANNOUNCED TODAY TO REDUCE SG&amp;A BY APPROXIMATELY $250 MILLION IN FISCAL 2022</p><p>   * HAS FURTHER REDUCED ITS PLAN FOR CAPITAL SPENDING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * WORKING EXPEDITIOUSLY TO INCREASE ITS NATIONAL BRANDS INVENTORY WHERE POSSIBLE</p><p>   * WILL INCREASE INVENTORY PENETRATION BY 20 PERCENTAGE POINTS OVER LONG TERM</p><p>   * BED BATH &amp; BEYOND- CONTINUES TO EVALUATE PORTFOLIO &amp; LEASES, IN ADDITION TO STAFFING, TO ENSURE ALIGNMENT WITH CUSTOMER DEMAND AND GO-FORWARD STRATEGY</p><p>   * BED BATH &amp; BEYOND - WILL BE EXITING A THIRD OF ITS OWNED BRANDS BY DISCONTINUING THREE OF ITS NINE LABELS (HAVEN™, WILD SAGE™ AND STUDIO 3B™)</p><p>   * BED BATH &amp; BEYOND - BREADTH AND DEPTH OF INVENTORY ACROSS COMPANY'S SIX REMAINING OWNED BRANDS WILL BE SUBSTANTIALLY REDUCED TO 20 PERCENTAGE POINTS</p><p>   * BED BATH &amp; BEYOND - COMPLETED A COMPREHENSIVE REVIEW OF INHERENT VALUE OF COMPANY'S BUYBUY BABY BANNER, WHICH CONFIRMED BANNER'S STRATEGIC POTENTIAL</p><p>   * SEES Q2 COMPARABLE SALES DECLINE OF APPROXIMATELY 26% COMPARED TO Q2 OF FISCAL 2021</p><p>   * BED BATH &amp; BEYOND - BOARD BELIEVES , AT THIS TIME, BUYBUY BABY WILL DELIVER GREATER VALUE FOR SHAREHOLDERS AS PART OF BED BATH &amp; BEYOND INC. PORTFOLIO</p><p>   * SEES COMPARABLE SALES DECLINE IN 20% RANGE DRIVEN BY IMPROVEMENTS IN SECOND HALF OF FISCAL 2022 VERSUS FIRST HALF OF FISCAL 2022</p><p>   * BED BATH &amp; BEYOND - BOARD OF DIRECTORS' STRATEGY COMMITTEE TO CONTINUE TO MONITOR BUYBUY BABY BUSINESS AS IT PRESERVES OPTIONALITY, <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> VALUE CREATION</p><p>   * MARA SIRHAL HAS BEEN APPOINTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BED BATH &amp; BEYOND</p><p>   * PATTY WU HAS BEEN PROMOTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BUYBUY BABY</p><p>   * HAS ELIMINATED CHIEF OPERATING OFFICER AND CHIEF STORES OFFICER ROLES</p><p>   * JOHN HARTMANN AND GREGG MELNICK WILL BE DEPARTING COMPANY</p><p>   * BED BATH &amp; BEYOND - FILED FORM S-3 REGISTRATION STATEMENT AS IT PREPARES FOR POTENTIAL LAUNCH OF ATM PROGRAM FOR UP TO 12 MILLION SHARES OF COMMON STOCK</p><p>   * Q2 REVENUE VIEW $1.50 BILLION -- REFINITIV IBES DATA</p><p>   * FY2022 REVENUE VIEW $7.88 BILLION -- REFINITIV IBES DATA</p><p>   * SEES Q2 NET SALES OF APPROXIMATELY $1.45 BILLION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-08-31 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Aug 31 (Reuters) - Bed Bath &amp; Beyond Inc   :</p><p>   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FINANCIAL POSITIONING, DRIVE GROWTH AND BETTER SERVE CUSTOMERS</p><p>   * SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * ANNOUNCED IT HAS SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * HAS BEGUN IMPLEMENTING SIGNIFICANT, ADDITIONAL SG&amp;A REDUCTIONS TO RIGHT-SIZE ITS COST STRUCTURE</p><p>   * BED BATH &amp; BEYOND - SECURED FINANCING COMMITMENTS INCLUDING ITS NEWLY EXPANDED $1.13 BILLION ABL FACILITY AND A NEW $375 MILLION FILO FACILITY</p><p>   * COST OPTIMIZATION PLANS INCLUDE A REDUCTION IN FORCE, INCLUDING APPROXIMATELY 20% ACROSS CORPORATE AND SUPPLY CHAIN</p><p>   * IDENTIFIED AND COMMENCED CLOSURE OF APPROXIMATELY 150 LOWER-PRODUCING BED BATH &amp; BEYOND BANNER STORES</p><p>   * EXPECTS ACTIONS ANNOUNCED TODAY TO REDUCE SG&amp;A BY APPROXIMATELY $250 MILLION IN FISCAL 2022</p><p>   * HAS FURTHER REDUCED ITS PLAN FOR CAPITAL SPENDING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * WORKING EXPEDITIOUSLY TO INCREASE ITS NATIONAL BRANDS INVENTORY WHERE POSSIBLE</p><p>   * WILL INCREASE INVENTORY PENETRATION BY 20 PERCENTAGE POINTS OVER LONG TERM</p><p>   * BED BATH &amp; BEYOND- CONTINUES TO EVALUATE PORTFOLIO &amp; LEASES, IN ADDITION TO STAFFING, TO ENSURE ALIGNMENT WITH CUSTOMER DEMAND AND GO-FORWARD STRATEGY</p><p>   * BED BATH &amp; BEYOND - WILL BE EXITING A THIRD OF ITS OWNED BRANDS BY DISCONTINUING THREE OF ITS NINE LABELS (HAVEN™, WILD SAGE™ AND STUDIO 3B™)</p><p>   * BED BATH &amp; BEYOND - BREADTH AND DEPTH OF INVENTORY ACROSS COMPANY'S SIX REMAINING OWNED BRANDS WILL BE SUBSTANTIALLY REDUCED TO 20 PERCENTAGE POINTS</p><p>   * BED BATH &amp; BEYOND - COMPLETED A COMPREHENSIVE REVIEW OF INHERENT VALUE OF COMPANY'S BUYBUY BABY BANNER, WHICH CONFIRMED BANNER'S STRATEGIC POTENTIAL</p><p>   * SEES Q2 COMPARABLE SALES DECLINE OF APPROXIMATELY 26% COMPARED TO Q2 OF FISCAL 2021</p><p>   * BED BATH &amp; BEYOND - BOARD BELIEVES , AT THIS TIME, BUYBUY BABY WILL DELIVER GREATER VALUE FOR SHAREHOLDERS AS PART OF BED BATH &amp; BEYOND INC. PORTFOLIO</p><p>   * SEES COMPARABLE SALES DECLINE IN 20% RANGE DRIVEN BY IMPROVEMENTS IN SECOND HALF OF FISCAL 2022 VERSUS FIRST HALF OF FISCAL 2022</p><p>   * BED BATH &amp; BEYOND - BOARD OF DIRECTORS' STRATEGY COMMITTEE TO CONTINUE TO MONITOR BUYBUY BABY BUSINESS AS IT PRESERVES OPTIONALITY, <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> VALUE CREATION</p><p>   * MARA SIRHAL HAS BEEN APPOINTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BED BATH &amp; BEYOND</p><p>   * PATTY WU HAS BEEN PROMOTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BUYBUY BABY</p><p>   * HAS ELIMINATED CHIEF OPERATING OFFICER AND CHIEF STORES OFFICER ROLES</p><p>   * JOHN HARTMANN AND GREGG MELNICK WILL BE DEPARTING COMPANY</p><p>   * BED BATH &amp; BEYOND - FILED FORM S-3 REGISTRATION STATEMENT AS IT PREPARES FOR POTENTIAL LAUNCH OF ATM PROGRAM FOR UP TO 12 MILLION SHARES OF COMMON STOCK</p><p>   * Q2 REVENUE VIEW $1.50 BILLION -- REFINITIV IBES DATA</p><p>   * FY2022 REVENUE VIEW $7.88 BILLION -- REFINITIV IBES DATA</p><p>   * SEES Q2 NET SALES OF APPROXIMATELY $1.45 BILLION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4178":"家庭装饰零售","BK4570":"地缘局势概念股","NGD":"New Gold","BK4017":"黄金","BK4547":"WSB热门概念","BBBY":"3B家居"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2263407776","content_text":"Aug 31 (Reuters) - Bed Bath & Beyond Inc   :   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FINANCIAL POSITIONING, DRIVE GROWTH AND BETTER SERVE CUSTOMERS   * SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING   * ANNOUNCED IT HAS SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION   * HAS BEGUN IMPLEMENTING SIGNIFICANT, ADDITIONAL SG&A REDUCTIONS TO RIGHT-SIZE ITS COST STRUCTURE   * BED BATH & BEYOND - SECURED FINANCING COMMITMENTS INCLUDING ITS NEWLY EXPANDED $1.13 BILLION ABL FACILITY AND A NEW $375 MILLION FILO FACILITY   * COST OPTIMIZATION PLANS INCLUDE A REDUCTION IN FORCE, INCLUDING APPROXIMATELY 20% ACROSS CORPORATE AND SUPPLY CHAIN   * IDENTIFIED AND COMMENCED CLOSURE OF APPROXIMATELY 150 LOWER-PRODUCING BED BATH & BEYOND BANNER STORES   * EXPECTS ACTIONS ANNOUNCED TODAY TO REDUCE SG&A BY APPROXIMATELY $250 MILLION IN FISCAL 2022   * HAS FURTHER REDUCED ITS PLAN FOR CAPITAL SPENDING   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION   * WORKING EXPEDITIOUSLY TO INCREASE ITS NATIONAL BRANDS INVENTORY WHERE POSSIBLE   * WILL INCREASE INVENTORY PENETRATION BY 20 PERCENTAGE POINTS OVER LONG TERM   * BED BATH & BEYOND- CONTINUES TO EVALUATE PORTFOLIO & LEASES, IN ADDITION TO STAFFING, TO ENSURE ALIGNMENT WITH CUSTOMER DEMAND AND GO-FORWARD STRATEGY   * BED BATH & BEYOND - WILL BE EXITING A THIRD OF ITS OWNED BRANDS BY DISCONTINUING THREE OF ITS NINE LABELS (HAVEN™, WILD SAGE™ AND STUDIO 3B™)   * BED BATH & BEYOND - BREADTH AND DEPTH OF INVENTORY ACROSS COMPANY'S SIX REMAINING OWNED BRANDS WILL BE SUBSTANTIALLY REDUCED TO 20 PERCENTAGE POINTS   * BED BATH & BEYOND - COMPLETED A COMPREHENSIVE REVIEW OF INHERENT VALUE OF COMPANY'S BUYBUY BABY BANNER, WHICH CONFIRMED BANNER'S STRATEGIC POTENTIAL   * SEES Q2 COMPARABLE SALES DECLINE OF APPROXIMATELY 26% COMPARED TO Q2 OF FISCAL 2021   * BED BATH & BEYOND - BOARD BELIEVES , AT THIS TIME, BUYBUY BABY WILL DELIVER GREATER VALUE FOR SHAREHOLDERS AS PART OF BED BATH & BEYOND INC. PORTFOLIO   * SEES COMPARABLE SALES DECLINE IN 20% RANGE DRIVEN BY IMPROVEMENTS IN SECOND HALF OF FISCAL 2022 VERSUS FIRST HALF OF FISCAL 2022   * BED BATH & BEYOND - BOARD OF DIRECTORS' STRATEGY COMMITTEE TO CONTINUE TO MONITOR BUYBUY BABY BUSINESS AS IT PRESERVES OPTIONALITY, FUTURE VALUE CREATION   * MARA SIRHAL HAS BEEN APPOINTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BED BATH & BEYOND   * PATTY WU HAS BEEN PROMOTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BUYBUY BABY   * HAS ELIMINATED CHIEF OPERATING OFFICER AND CHIEF STORES OFFICER ROLES   * JOHN HARTMANN AND GREGG MELNICK WILL BE DEPARTING COMPANY   * BED BATH & BEYOND - FILED FORM S-3 REGISTRATION STATEMENT AS IT PREPARES FOR POTENTIAL LAUNCH OF ATM PROGRAM FOR UP TO 12 MILLION SHARES OF COMMON STOCK   * Q2 REVENUE VIEW $1.50 BILLION -- REFINITIV IBES DATA   * FY2022 REVENUE VIEW $7.88 BILLION -- REFINITIV IBES DATA   * SEES Q2 NET SALES OF APPROXIMATELY $1.45 BILLIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9995746673,"gmtCreate":1661524004094,"gmtModify":1676536534951,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going&nbsp;","listText":"Keep going&nbsp;","text":"Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9995746673","repostId":"2262927014","repostType":2,"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}